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ABSTRACT OF THE THESIS 
 
  
An Evaluation of Variants Associated with 176 Conditions Identified through Exome 
Sequencing in an Armenian Sample 
  
By 
  
Aida Natalie Akopyan 
  
Master of Science in Genetic Counseling 
  
University of California, Irvine, 2019 
  
Professor Robert K. Moyzis, Chair 
  
  
  
This study aims to shed light on genetic variation among Armenians, an understudied 
population. Given the increasing uptake of genetic testing in various settings, the lack of 
published research poses a significant barrier to providing precise and thorough genetic 
counseling to Armenian individuals. By analyzing exome sequence from 44 Armenian 
individuals for 176 genes related to conditions commonly tested for in expanded carrier 
screening, expanded carrier screening positive rates (ECS-PRs) were calculated for individuals in 
this study. Fifty-two percent of individuals in this cohort were found to be a carrier of a 
pathogenic variant for at least one recessive condition. A total of seven out of 44 individuals 
were found to be carriers for familial Mediterranean fever; however, when FMF was excluded 
from ECS-PR calculation, the percentage of individuals who were found to be a carrier of a 
pathogenic variant for at least one recessive condition only decreased by 4%, yielding an ECS-
PR of 48%. There were also two individuals with the same CFTR pathogenic variant, four 
individuals with four distinct PAH variants, and two individuals with two distinct PMM2 
variants. This study provides data to a recommendation of expanded carrier screening in 
Armenian individuals as compared to targeted testing for FMF only. Results of this study will 
improve genetic counseling provided to Armenian individuals, particularly in prenatal and pre-
ix 	  
conceptional settings, and promote diversity and equity in the field of genetics to improve the 
overall quality of services for providers and patients alike. 
1 	  
I. INTRODUCTION 
I.I. The Importance of Population Genetics and a Human Reference Genome 
 The study of human population genetics has been a focus for scientists for many years, 
well before the advent of complex sequencing technologies or the establishment of a human 
reference genome.  Population genetic studies aim to identify genetic differences within and 
between different populations, and by doing so, provide insight into evolution, natural selection, 
genetic drift, and clinical interpretation of genetic variants. Ancient populations that have 
remained isolated from other populations for many years can be a desirable study cohort because 
of their higher level of genetic homogeneity, which in turn allows for a smaller effective sample 
size in characterizing genetic variability [Hatzikotoulas et al., 2014]. In addition to this, the 
persistence of some variants in an isolated population may demonstrate that a variant has an 
adaptive advantage, especially since isolated populations tend to be exposed to the same 
environmental and cultural influences [Gibbs et al., 2015]. Isolated populations also typically 
show longer regions of non-random association of genetic factors, otherwise known as linkage 
disequilibrium, which aid in clarifying disease association loci. When two or more genetic 
factors are inherited together more often than expected, these form haplotype blocks that can be 
tracked over multiple generations. However, with longer haplotype blocks, it is more difficult to 
pinpoint the causal variant for a condition of interest. Therefore, the optimal method to identify 
disease related loci through association studies is to perform analyses in multiple different ethnic 
populations, including isolated populations, in order to narrow in on regions of interest for 
various genetic conditions [Hatzikotoulas et al., 2014]. 
In order to better understand why it is important to study the genetics of isolated, non-
European white populations, it is helpful to reflect on the development of the human reference 
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genome. For centuries, people have been fascinated by what makes humans different from other 
species and from one another, but it wasn’t until the early-mid 20th century that greater advances 
were made towards discovering the basis of these differences. Researchers James Watson and 
Francis Crick first proposed the double helix as the structure of DNA in 1953, and as DNA 
sequencing eventually became automated, the Human Genome Project was officially initiated in 
1990 [Pray, 2008; International Human Genome Sequencing Consortium, 2004]. Many of the 
formative years of the project were focused on improving efficiency of sequencing and other 
methodologies. Even prior to the project’s formal proposal, scientists in 20 sequencing centers 
from six different countries began collaborating on this international project, which they believed 
would change the scientific community and healthcare practices forever [What a long, strange 
trip it’s been. . ., 2001]. Volunteers for DNA collection were sought out through advertisements 
placed in neighborhoods around the sequencing centers, and ultimately many more samples were 
collected than were actually used in the project. Thus the identities of the individuals’ genomes 
analyzed remained anonymous, even to the volunteers themselves. In February of 2001, 90% of 
the Human Genome project was published as a draft, and it eventually revealed that there are 
approximately 20,000 genes in the human genome rather than 100,000 as was previously 
estimated [International Human Genome Sequencing Consortium, 2004]. The completed 
sequence was released in 2004 and covered approximately 99% of the euchromatic genome. This 
included the majority of gene-rich portions and transcriptionally active regions of the genome, 
with only 341 sequence gaps and an error rate of about 1 per 100,000 base pairs. This was 
greatly reduced from the draft sequence, which initially contained approximately 150,000 gaps 
[International Human Genome Sequencing Consortium, 2004]. Gap resolution was difficult due 
to regions of the genome where there are substantial sequence similarities, such as with 
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segmental duplications and other repetitive sequences. In order to tackle these challenges, the 
project utilized PCR and traditional sequencing methods to obtain a sequence that bordered a 
gap. Research scientists in the project then used the ends of these sequences as the primers for 
the gap region and completed long-range sequencing into the gap regions, a method known as 
primer walking. These methods were largely effective in continuing sequencing into the gaps and 
resulted in the vast majority of them being resolved in the finished sequence. With the majority 
of artifactual duplications being resolved, further studies of known duplicated segments such as 
the 22q DiGeorge region, the 17p Charcot-Marie-Tooth region, and the Y chromosome became 
possible. In addition to this, the development of a reference genome has aided in the 
identification and annotation of all protein coding regions of the genome, which has proven 
essential for improving the understanding of disease mechanism and etiology. Lastly, the 
presence of the sequence has provided a gateway into exploring genetic adaptation through the 
birth of new genes and creation of pseudogenes through gene death [International Human 
Genome Sequencing Consortium, 2004]. These are just a few examples of the clinical utility of a 
near-complete human reference sequence. 
The establishment of a human reference genome also allowed for the development of 
multiple testing methodologies such as gene chip arrays; however, limitations of the reference 
quickly became apparent. Given that the majority of the individuals whose genomes were used 
during the establishment of the human reference genome were of European ancestry, many 
unique SNPs that are seen only in some populations were likely not discovered, which resulted in 
a reference sequence that was not necessarily representative of all different ethnicities. Probes 
that were created to match certain regions of the genome for sequencing and amplification have 
proven difficult to design due to genetic variation between individuals across different 
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populations. Single nucleotide polymorphisms within the probe regions hinder proper 
sequencing, and the presence of these SNPs varies across individuals and populations [Rosenfeld 
et al., 2012]. The HapMap Consortium and the 1000 Genomes project have attempted to address 
this disparity to a large extent. 
The HapMap project, which was completed in two phases, aimed to characterize a large 
proportion of SNPs found in 270 individuals from geographically distinct areas. Phase II of the 
project was able to capture over 3.1 million common SNPs and provide insight on linkage 
disequilibrium and the distribution and frequency of the changes. The study also found that 10-
30% of individuals from the same population share at least one region of extended genetic 
identity [Frazer et al., 2007]. By creating a more robust archive of common SNPs and learning 
more about haplotypes and recombination events, the project allowed for genome-wide 
association studies to become a more widely available tool for studying common genetic 
conditions such as cancer and cardiovascular disease.  
The 1000 Genomes project was designed to increase the number of variants reported in 
human genomes by analyzing 2,504 individual genomes from 26 different populations [Gibbs et 
al., 2015]. The project identified more than 80 million variants, the vast majority of which were 
single nucleotide polymorphisms (SNPs). The study has estimated that it includes >99% of SNPs 
with a frequency of greater than 1% across multiple ancestries. Interestingly, while sequences 
from individuals of African ancestry showed greater levels of diversity, this did not correlate to 
the number of disease-related variants identified in these individuals. The highest yield for 
pathogenic alleles was seen in individuals of European ancestry, likely due to the fact that these 
populations have been studied in greater detail than non-European populations, and therefore 
alleles in these individuals are detected and interpreted more readily [Gibbs et al., 2015]. For this 
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reason, it is of the utmost importance to explore both common and rare genetic variants across all 
populations, in order to better characterize the clinical significance of variants for both 
Mendelian and common disorders.  
While many population studies such as these have been performed, the findings of these 
studies have only emphasized the importance of continuing this work and how it is essential to 
study as many different populations as possible. While international genome-wide association 
studies may prove beneficial in encouraging collaboration and sample diversity, the benefit of 
studying homogeneous populations remains a constant. Certain polymorphisms and pathogenic 
changes have likely arisen in isolated populations, and without performing more detailed studies 
in populations across the globe, the extent of genetic diversity cannot be fully known.  
As the emphasis on personalized medicine has grown over recent years, the importance 
of understanding genetic variation across populations has only increased. Although sequencing 
technologies have improved drastically, recent studies have shown that the technologies are not 
without flaws. The detection of low to moderate frequency variants (<5%) in population 
databases poses the question of whether these variants are truly present in individuals or if they 
represent some sequencing error in the technology. While many of these variants may be due to 
DNA polymerase sequencing errors, recent evidence has shown that variants introduced into the 
sample prior to PCR amplification are a cause for some of these low to moderate frequency 
sequencing calls, likely due to the introduction of changes early on in sequence amplification 
[Chen et al., 2017]. The presence of these variants results in confusion with interpretation of 
variants. Many widely used databases have incorrectly reported some of these variants in their 
repositories, particularly in G-to-T variant reads [Chen et al., 2017].  
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Exome sequencing has facilitated deeper analyses of genetic variation across different 
populations, although the interpretation of rare variants identified in select populations still 
remains a challenge. With exome sequencing, nearly all of an individual’s protein-coding 
information is sequenced, often yielding never-before-seen sequence variants, which can provide 
further insight on genetic diversity. Additionally, the prevalence of alleles which are associated 
with a variety of conditions, such as cystic fibrosis and phenylketonuria, can be elucidated with 
exome sequencing, which can help in guiding better risk assessment and counseling of patients. 
Recognition of the limits of our understanding of variation in the human genome across 
populations has sparked the interest of many. Individuals of some ethnic groups have even begun 
studying genetic variation of different populations in order to better characterize all variants. 
Until very recently, such studies have not been carried out in individuals of Armenian ancestry. 
 
I.II. Armenian Genetic Evolution and Migration Patterns 
The Republic of Armenia is a small nation located just below the Caucasus Mountain 
range, in a region historically referred to as the Near East. Armenia has an ancient history which 
dates back to before the Bronze age, and evidence has shown that Armenian farmers of the Near 
East admixed with other populations who migrated to Europe during the Neolithic [Haber et al., 
2015]. A 2015 study collected a set of 173 Armenian samples from Armenia and Lebanon and 
performed genome-wide analysis to compare Armenian genetic variation with 78 other 
populations worldwide. Results showed that Armenians cluster with other ethnic groups of (1) 
European, (2) Near Eastern, and (3) Caucasus origins. In particular, Armenians were genetically 
closest within these groups to (1) Spaniards, Italians, Romanians, (2) Lebanese, Jews, Druze, 
Cypriots, (3) Georgians, and Abkhazians [Haber et al., 2015]. Multiple mixture events were 
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shown to have occurred, initially around 3800 BCE between sub-Saharan Africans and Western 
Europeans, then Sardinians and Caucasus groups, and lastly multiple Eurasian peoples. 
However, after approximately 1200 BCE, Armenian admixture with other populations seems to 
have ceased, creating a population that has been genetically isolated for the last 3000 years 
[Haber et al., 2015].   
While Armenia is a land-locked country, it once spanned from sea to sea, reaching the 
Mediterranean, and encompassing much of what is now called Eastern Turkey. The shifts in its 
territorial holdings, migration patterns, and genetic admixture have repeatedly been influenced 
by conflicts with other nations. Similar to Lebanese Christians and Sephardic Jews, cultural, 
religious, and ethno-linguistic differences between Armenians and their neighbors resulted in the 
creation of a genetically isolated population. In 1915 CE, these differences greatly contributed to 
what became known as the Armenian Genocide, the extermination of nearly 1.5 million 
Armenians. In the midst of World War I, Armenians were displaced from their ancestral homes 
in current-day Eastern Turkey, and mass deportations resulted in many moving to the United 
States, Canada, France, Germany, Lebanon, Syria, Iran, and Egypt [Chaloyan, 2017]. Following 
these events, Armenia was taken over by the USSR and remained as a member of the Soviet 
Union for the majority of the 20th century, until it regained independence in 1991 [Chaloyan, 
2017]. As the Armenian diaspora grew and living conditions suffered under new leadership, 
families encouraged their loved ones to also emigrate to countries like the U.S. This ultimately 
resulted in another wave of migration with 610,000 people exiting the country between 1991-
1995.  
Currently, reports claim that approximately 3.5 million Armenians remain in the 
Republic of Armenia, while there are between 7.5-8 million Armenians in the diaspora 
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[Chaloyan, 2017]. Many of these individuals reside in California, particularly Los Angeles, and 
other cities along the East Coast. The formation of different diaspora populations has also 
contributed to a slight genetic divergence even among Armenians. Armenians who 
predominantly left the region following the events of 1915, sometimes referred to as Western 
Armenians, can be differentiated from Armenians who resided in Eastern, or modern day 
Armenia [Haber et al., 2015]. However, the Armenian clusters were significantly more similar in 
genetic structure to one another than they were to other populations, reaffirming that the 
population has been genetically isolated for many years. Research in recent years has 
demonstrated the value of studying isolated populations in order to learn more about rare variant-
phenotype associations, gene-environment interactions, and genetic diversity between and 
among populations [Haber et al., 2015]. This study will aim to do just that, by characterizing a 
small, healthy Armenian population’s genetic variation. With regards to Armenians, one cannot 
speak of genetic conditions without discussing familial Mediterranean fever. 
 
I.III. Familial Mediterranean Fever - the most common hereditary condition in Armenians 
Familial Mediterranean fever (FMF) is a genetic condition that is found at a higher 
frequency in individuals of Armenian ancestry. FMF is an autosomal recessive condition that is 
most often associated with recurrent episodes of high fever, inflammation and severe abdominal 
pain [Shohat and Halpern, 2011]. The condition can be categorized into two types: type 1 and 
type 2. In type 1, febrile and inflammatory episodes usually begin in early childhood or 
adolescence. In adulthood, there is an increased risk for amyloidosis, a build-up of abnormal 
protein in an organ, and eventual end-stage renal disease, particularly if individuals are untreated. 
In individuals with type 2 FMF, amyloidosis in adulthood is often the presenting feature of the 
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condition. Individuals with FMF are typically treated with colchicine, which greatly reduces the 
likelihood of febrile and inflammatory episodes, as well as amyloidosis [Shohat and Halpern, 
2011]. For individuals who seek treatment early in life and continue management into adulthood, 
the prognosis for FMF is quite good. Interestingly, some individuals who are diagnosed with 
FMF only have one identified mutation in the associated gene, MEFV. One study found that up 
to 25% of individuals diagnosed with FMF may be heterozygotes; therefore, it is difficult to 
determine if these individuals are truly affected due to a single mutation or if other modifying 
factors play a role as well [Marek-Yagel et al., 2009]. The most common variants seen in FMF 
carriers are p.M694V, p.M694I, p.V726A, p.E148Q, and p.M680I. The carrier frequency of FMF 
in Armenian individuals is approximately 1 in 5; therefore, the reproductive risk for Armenian 
couples is quite high and warrants consideration of carrier testing for these couples [Sarkisian et 
al., 2008]. While there has been negligible interest in pregnancy termination for the condition, 
some couples may find that the knowledge that they are at risk to have a child with FMF can 
help them to identify the early signs of the condition and therefore implement treatment earlier 
on.  
In addition to FMF, Armenians are at risk for other recessive conditions, just as 
individuals of all populations are, regardless of ancestry. Many of these conditions could pose 
greater health risks to an individual than FMF typically does. With continued advancements in 
sequencing and variant analysis, the availability of carrier screening panels has grown 
tremendously, and the uptake of expanded carrier screening is only increasing. In this study, the 
predicted performance of one of the most common commercially available expanded carrier 
screening panels which tests for 176 conditions will be evaluated in an Armenian population. 
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The following section will review how carrier screening has evolved over the years and how 
expanded carrier screening has become widely used in the clinical setting. 
 
I.IV. Expanded Carrier Screening 
 Carrier screening is genetic testing that is performed to determine if an individual is at an 
increased risk to have a child with a certain genetic condition. The majority of carrier screening 
is for autosomal recessive and X-linked recessive conditions, in which carriers typically do not 
express any features of the condition. If two individuals who mate are carriers for pathogenic 
variants in the same gene related to a genetic condition, there is a 25% chance to have a child 
affected with the condition [Bajaj and Gross, 2014]. Traditionally, carrier screening was 
performed for individuals who were expected to be at high risk for certain genetic conditions, 
either due to their ancestry or family history. For example, individuals of Ashkenazi Jewish 
ancestry might seek counseling and screening for conditions such as Tay-Sachs disease, and 
African Americans might choose to have screening for sickle cell anemia. However, many 
ethical dilemmas arose throughout the 20th century due to targeted ethnic carrier screening. 
Individuals were often discriminated against by employers, the military, or society in general, 
and relations between individuals of certain populations became tense [Fulda and Lykens, 2006]. 
Eventually, carrier screening practices changed by making testing options more universal to all 
individuals, regardless of a priori risk.  Both the American College of Medical Genetics and the 
American College of Obstetricians and Gynecologists now recommend offering carrier testing 
for two recessive conditions, cystic fibrosis (CF) and spinal muscular atrophy (SMA), to all 
women during pregnancy or preconceptionally [Grody et al., 2013; Romero et al., 2017]. In 
addition to these two, carrier screening for inherited forms of anemia, known as 
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hemoglobinopathies, is also offered to most individuals who are from a high-risk ethnicity group. 
Although targeted carrier screening is effective to an extent, given the major advances in 
sequencing technologies and the plummeting costs of testing, expanded carrier screening for all 
individuals, regardless of a priori risk, is becoming quite popular [Henneman et al., 2016]. 
Expanded carrier screening (ECS) allows for an individual to determine their carrier 
status for multiple, often over one hundred, genetic conditions simultaneously. Much like 
traditional carrier screening, ECS typically screens for the most common autosomal recessive 
and X-linked conditions that are seen across populations. The American College of Medical 
Genetics (ACMG) released recommendations in 2013 to aid genetic testing laboratories in the 
selection of conditions to be screened for on ECS panels [Grody et al., 2013]. The exact 
language used in the recommendations is as follows: 
 
1. Disorders should be of a nature that most at-risk patients and their partners 
identified in the screening program would consider having a prenatal diagnosis to 
facilitate making decisions surrounding reproduction. 
2. When adult-onset disorders (disorders that could affect the offspring of the individual 
undergoing carrier screening once the offspring reaches adult life) are included in 
screening panels, patients must provide consent to screening for these conditions, 
especially when there may be implications for the health of the individual being 
screened or other family members. 
3. For each disorder, the causative gene(s), mutations, and mutation frequencies should 
be known in the population being tested, so that meaningful residual risk in 
individuals who test negative can be assessed. 
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4. There must be validated clinical association between the mutation(s) detected and the 
severity of the disorder. 
5. Compliance with the American College of Medical Genetics and Genomics Standards 
and Guidelines for Clinical Genetics Laboratories, including quality control and 
proficiency testing. 
 
Given major advancements in technology and the increasing knowledge of genetic testing in 
society, largely due to the propagation of direct-to-consumer genetic testing, general population 
screening for multiple conditions is likely to become the new standard of practice. While there 
are many benefits to ECS, such as providing couples with significantly more information on their 
risks for certain genetic conditions, it is important to remain cautious about how ECS is 
implemented clinically. As the ACMG recommended, couples should be allowed to decide 
whether or not they would like to be informed about risks for conditions that have variable 
expressivity or reduced penetrance, particularly if the condition is typically mild [Grody et al., 
2013]. Interestingly, FMF is one such condition in which the utility of inclusion on ECS panels 
has been questioned, particularly because individuals at risk to have a child with FMF often do 
not consider prenatal testing and the condition does not always present in childhood. However, 
given that the condition can be life threatening if amyloidosis develops and given the high carrier 
frequency in some populations, the condition has consistently been included on many ECS 
panels. Accurate and comprehensive information regarding the residual risks for the conditions is 
also of the utmost importance when carrier screening results are reported out to individuals since 
ECS is a form of screening and will not detect all carriers for any given condition. Two recent 
American studies showed that between 25%-30% of individuals who underwent carrier 
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screening using an ECS panel which included approximately 400 known pathogenic variants 
were found to be a carrier for at least one condition [Peyser et al., 2018; Lazarin et al., 2013]. 
Two other studies which were performed in Spain reported values as high as 56%-84%, although 
these two studies included screening of 200 and 549 genes, respectively [Abulí et al., 2016; 
Martin et al., 2015]. Thus, the number of genes analyzed in the ECS panels and the 
methodologies used in these studies, which ranged from targeted genotyping of common variants 
to next-generation sequencing (NGS), varied greatly and likely impacted the number of carriers 
that were identified in each of the studies. Estimates of the yield of ECS panels may continue to 
increase as ECS panels become larger. ACMG recommends genetic counseling for all couples 
that are interested in ECS, as well as more detailed post-test counseling in the event of positive 
results [Grody et al., 2013].  
The American College of Obstetricians and Gynecologists (ACOG) has also issued 
multiple position statements regarding carrier screening. In position statement 690, ACOG’s 
recommendations for including a condition on an ECS panel are that the condition have a carrier 
frequency of 1 in 100 or greater, that the condition have a well-defined phenotype, that the 
condition have a detrimental effect on quality of life for most affected individuals, that the 
condition possibly cause cognitive or physical impairment, that the condition typically require 
medical or surgical intervention, that the condition often have a childhood onset, and that there 
be prenatal diagnosis available for the condition [Rink et al., 2017]. In position statement 691, 
ACOG presents guidelines for testing considerations based on the patient’s ethnicity [Romero et 
al., 2017]. While there is significant overlap between the recommendations from ACMG and 
ACOG, there are a few differences.  
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Notably, ACOG’s 1 in 100 carrier frequency criterion from position statement 690 is 
limiting in the number of conditions that should be included in ECS, as shown by a recent study 
[Ben-Shachar et al., 2019].  The study was conducted using data from couples that underwent 
ECS for 176 conditions offered through a widely used commercial laboratory. Carrier rates and 
at-risk couple rates were elucidated based on three different types of panels recommended by 
ACOG. The first panel consisted of 172 of the 176 conditions originally on the ECS panel since 
these 172 met at least 6 of the 7 ACOG 690 criteria. The second panel that was considered was 
based on the ethnicity-specific recommendations highlighted in ACOG’s committee opinion 691 
[Romero et al., 2017]. The last panel included testing for only cystic fibrosis and spinal muscular 
atrophy, since these two conditions are recommended for testing in all ethnicities [Ben-Shachar 
et al., 2019]. With a 172 condition panel, carrier identification and at-risk couple detection each 
decreased by 3% as compared to the 176 condition panel. When the ACOG 691 panel was used, 
this decreased carrier identification by 77% and at-risk couple detection by 66% as compared to 
the 176 condition panel. Lastly, with CF and SMA only, carrier identification decreased by 88% 
and at-risk couple detection decreased by 84% as compared to the 176 condition panel [Ben-
Shachar et al., 2019].  
One can see that although the guidelines were aimed to improve overall clinical practices, 
and some may argue that they do, this study showed that the number of at-risk couples that 
would be identified if such stringent criteria were used is lower when using some of ACOG’s 
recommended criteria. With regard to the 1 in 100 criteria, the study considered three different 
definitions for how this could be interpreted: a 1 in 100 carrier rate in any ethnicity, a 1 in 100 
US-weighted carrier rate, or a 1 in 100 carrier rate in all ethnicities. Using one of these 
definitions, carrier screening panels would test between 3 and 38 conditions, which would reduce 
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carrier detection rates by 36%-79% and at-risk couple detection rates by 11%-92%. As 
previously stated, the benefit of ECS is that it identifies a greater number of at-risk couples. 
However, identifying additional carriers may incur greater costs for insurance companies and 
patients since some individuals might use knowledge of their carrier status in order to pursue 
further testing, such as carrier screening in their partner, in vitro fertilization (IVF), or 
preimplantation genetic testing for monogenic/single-gene disorders (PGT-M). The study 
performed a cost-benefit analysis by comparing the number of at-risk couples identified, which is 
the benefit of ECS, to the number of carriers identified, which is one of the costs of ECS and was 
the focus in this paper [Ben-Shachar et al., 2019]. They found that adding rarer conditions to the 
panel helped to increase the number of at-risk couples identified and that the relationship 
between the number of at-risk couples identified to the number of carriers identified was roughly 
linear until a condition carrier rate of approximately 1 in 1000 [Ben-Shachar et al., 2019]. Thus, 
Ben-Shachar et al. infer that it may be worthwhile to include conditions on ECS panels with a 
carrier rate of 1 in 1000 or more frequent, since adding more conditions tends to increase the 
number of at-risk couples detected, which is the presumed benefit of performing ECS, without 
disproportionately increasing insurance-related costs. However, for very rare conditions where 
many variants identified would not be able to be classified as pathogenic or benign, the clinical 
utility would be very low and would not provide as much useful information to couples or inform 
them of their residual risk [Ben-Shachar et al., 2019]. This concept provides yet another reason 
why it is critical to perform more research in understudied populations, since this would help to 
increase the clinical detection for individuals of these populations.  
Given the increasingly complex considerations that must be discussed regarding ECS, 
genetic counseling has become more imperative than ever. Genetic counselors frequently 
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confront difficult discussions with patients due to the growing number of testing options, and 
therefore it is important to provide counselors with as many tools as possible to aid in counseling 
individuals of different backgrounds. Although ethnicity is often a key consideration when 
counselors discuss the availability of different types of prenatal and preconception testing, there 
are many ethnicities in which specific carrier frequencies or even estimates are not well known, 
including Armenians. Thus, further discussion and studies are necessary in order to increase the 
amount of information available to genetics professionals in order to provide patients with more 
accurate and culturally sensitive information. 
 
IV. Genetic Counseling 
The National Society of Genetic Counselors defines genetic counseling as “the process of 
helping people understand and adapt to the medical, psychological and familial implications of 
genetic contributions to disease” [Resta et al., 2006]. Indeed, genetic counseling is a process in 
that it requires an extensive knowledge of a wide array of genetic conditions and the ability to 
interpret family and medical histories to assess the likelihood of a given condition. Genetic 
counselors also provide education, resources, and support to patients and other clinicians. At the 
core of genetic counseling values is the belief that all individuals should be given the opportunity 
to make informed decisions regarding their own medical care, and it is the genetic counselor’s 
job to aid in this decision-making. Over the years, genetic counseling has expanded as a 
profession, especially in the last two decades following major advancements in molecular 
technologies. While the majority of genetic counselors in practice are women of European 
ancestry, there are a growing number of individuals from different cultural backgrounds who are 
seeking genetic counseling services [Mittman and Downs, 2008]. Recent U.S. Census data, as 
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well as studies from the 2010 Census, have shown that there are a growing number of individuals 
in the U.S. reporting non-white and multiracial backgrounds [U.S. Census Bureau, 2012]. This is 
primarily due to marriage between individuals of different cultures, which will undoubtedly 
continue to happen at an increasing rate in America.  
Given these trends, many professionals are arguing for the use of expanded carrier 
screening rather than ethnicity-based screening in all women of reproductive age, given that the 
latter would fail to detect many carriers and at risk couples that would not meet recommended 
criteria for testing [Peyser et al., 2018]. The American College of Medical Genetics and 
Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic 
Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine released a 
joint statement in 2015 providing recommendations for counseling about ECS to patients 
[Edwards et al., 2015]. The statement recommends that patients should be counseled on basic 
information about the conditions being screened for and the detection rates for these, although it 
would not be possible to discuss each condition in detail. The statement also provided insight on 
future needs to improve ECS, which includes development of a repository of curated variants, 
which would be made possible through extensive pan-ethnic genotyping. As genetic counselors, 
it is important to be aware of what testing is appropriate to offer to individuals, not only based on 
published society recommendations, but also on a patient-specific basis. Different individuals 
have differing comfort levels with knowing more or less information, so it is important to discuss 
both the benefits and limitations of ECS and other carrier screening options with patients. 
Additionally, as previously mentioned, the clinical utility of ECS for some ethnicities is lower 
since it can be more difficult to interpret variants identified in understudied populations. 
Therefore, it is critical to emphasize that ECS is not a diagnostic tool, but rather a screening tool 
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that is designed to have a high detection rate for the majority of conditions tested in as many 
ethnicities as possible, but that ultimately it is not designed to detect all possible changes or 
conditions that a person could carry. This truth should especially be emphasized in individuals of 
non-European ancestry, at least until more studies are completed to better identify disease-
causing and benign variation across all populations. 
 
I.VI. Significance and Aims of this Study 
 Given the lack of published research on the Armenian community and the increasing 
uptake of expanded carrier screening and other forms of genetic testing, this study will aim to 
better understand genetic variation among Armenians. Studies have shown that the percentage of 
individuals that are detected to be a carrier for at least one condition when expanded carrier 
screening is completed can be quite high in some populations [Peyser et al., 2018; Abulí et al., 
2016; Martin et al., 2015; Lazarin et al., 2013]. By analyzing exome sequences from 44 
Armenian individuals for 176 conditions that are included in one commercially available 
expanded carrier screen (Appendix B), the expanded carrier screening positive rate (ECS-PR) 
can be estimated for individuals of this ethnicity. Additionally, this score can be compared to 
estimates proposed by other studies in the literature, primarily in individuals of European 
ancestry. Since it is already known that there is a high carrier frequency for FMF in Armenians, 
this study will also aim to identify the likelihood of receiving a positive carrier screen result for 
other conditions. I hypothesize that the ECS-PR in Armenians will be similar to previously 
reported rates in other populations; however, if FMF were to be removed from analyses to 
evaluate for the ECS-PR without the condition, I hypothesize that the ECS-PR in Armenian 
individuals will be lower than previously reported rates in other populations. 
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 Another goal of this study is to investigate rare variants that may be identified in this 
sample, some of which have likely been previously reported in databases as being of uncertain 
significance. This study may also identify variants that have not been seen in other populations 
thus far. I hypothesize that all of the individuals will have variants that are of unknown 
significance or that have not been seen before. It is likely that some of the genes in the expanded 
screen are better studied than others, and may have fewer never-before-seen variants. However, 
given that Armenians are an understudied population, I hypothesize that there will be many 
novel variants identified. To our knowledge, this study is the first of its kind in the Armenian 
population. Overall, the goal of this study is to provide more information to the public and 
medical professionals about Armenian genetic variation. More comprehensive studies are 
necessary in this population in order to improve public health and medical care in both Armenia 
and for Armenians in the diaspora. The hope is that this information will improve genetic 
counseling provided to individuals of Armenian ancestry, particularly in prenatal and pre-
conceptional settings, and to encourage others to pursue similar studies in other ethnic 
populations. Knowledge of carrier status is an important piece of information for many couples 
that are planning a family, and as information grows about genetic variation in the Armenian 
population specifically, testing may become more available and attractive to individuals of the 
population. This would promote diversity and equity in the field of genetics, and improve the 
overall quality of services for providers and patients alike. 
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II. METHODS 
II.I. The ArmGenia Project 
 In 2015, a group of Armenian investigators received seed funding from Sara Chitijian, a 
UCLA alumna and daughter of a Genocide survivor, in order to begin an Armenian Reference 
Genome project. Drs. Sevak Avagyan and Evgeni Sokurenko, co-founders of the ArmGenia 
Research Charitable Trust, teamed up with the UCLA Center for World Health and Dr. Wayne 
Grody, professor of pathology and laboratory medicine, pediatrics, and human genetics at the 
David Geffen School of Medicine at UCLA in order to pursue the ArmGenia project. Their 
primary goal was to shed light on the genetic origins of the Armenian people, in order to increase 
knowledge and improve healthcare for Armenians, especially for FMF [Djourabchi, 
https://www.worldhealth.med.ucla.edu/index.php/ucla-armgenia-mou-signing-mapping-of-the-
armenian-genome/, accessed April 5 2019].   
 
II.II. IRB Approval 
 The ArmGenia project has Institutional Review Board (IRB) approval in Yerevan, 
Armenia. An agreement was drafted with UCLA in order to have data primarily analyzed at 
UCLA. Dr. Wayne Grody and Dr. Salpy Akaragian, former director of the UCLA International 
Nursing Program and primary liaison to the ArmGenia Research Charitable Trust, have 
determined that no further IRB approval is necessary since the data that was utilized in this study 
is completely de-identified. Additionally, a Request for Determination of Human Studies 
Research was submitted to the UCI IRB, and it was confirmed that this project “does not qualify 
as human subjects research because the activities do not involve human subjects given that all 
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data will be de-identified. Therefore, the activities are not subject to UCI IRB review and 
approval.” This email statement was received on 11/28/2018 from the UCI IRB office.  
 
II.III. Data Collection and Sample Information 
 The initial set of samples of the ArmGenia project was collected from 25 unrelated and 
healthy Armenian individuals who were at least 60 years old at the time that they enrolled in the 
project. At a later date, a second set of samples was collected from 19 individuals who were also 
unrelated and healthy Armenian individuals and at least 60 years old at the time that they 
enrolled in the project. The 44 individuals originated from multiple regions across Armenia, 
Nagorno-Karabakh, and what was formerly known as Western Armenia. No additional 
information is known about the individuals whose exomes were sequenced.  
 
II.IV. Exome Sequencing 
Exome sequencing and analysis was performed in two separates batches at UCLA using 
the following identical pipeline for each. Raw FASTQ files were aligned in a cloud-based 
pipeline using BWA-MEM software. Raw alignments were checked for quality using GATK 
HaplotypeCaller by calculating the Genotype Quality (GQ). The GQ is calculated using Phred-
scaled likelihood (PL) scores, which are defined as PL=−10∗logP(Genotype|Data). The GQ is 
the difference between the PL of the second most likely genotype, and the PL of the most likely 
genotype, and the highest possible confidence value is 99. Variant calling was performed using 
GATK HaplotypeCaller using joint variant calling, meaning that a set of previously sequenced 
samples were combined with the novel samples of interest in order to reduce calling bias and 
false positivity. The two batches (25 samples and 19 samples, respectively) were each processed 
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with a similar-sized sample of non-Armenian individuals. Data from these non-Armenian 
individuals were later omitted during data analysis. Variant calls were recalibrated and recalled 
for short indel detection. Two separate VCF files with the 25 and 19 samples were created and 
included single nucleotide variants (SNVs) and short indels. Within the respective VCF files the 
chromosome position, genotype, allelic depth, read depths, genotype quality, and variant allele 
frequency were included for each of the individual samples. Variants were annotated using 
VarSeq® version 2.1.0 (Golden Helix, Inc., Bozeman, MT), as is outlined in the following 
section. 
 
II.V. Variant Annotation and Filtration 
 
VarSeq® is a software that can be used to annotate large variant data sets. VarSeq® 
imports variant annotation information directly from a number of different sources. This study 
utilized annotations provided by RefSeq Genes 105 Interim v1, NCBI 
(https://www.ncbi.nlm.nih.gov/refseq/rsg/) and ClinVar (data frozen from 2017-09-05, NCBI; 
https://www.ncbi.nlm.nih.gov/clinvar/) [Pruitt et al., 2012; Landrum et al., 2016]. VCF files of 
the UCLA exome data were imported into VarSeq® for analysis. 
Variants were filtered to include only those in the genes associated with the 176 
conditions tested for in the Foresight (Myriad Women’s Health, South San Francisco, CA) 
expanded carrier screen, henceforward to be referred to as the ECS panel, which is available 
commercially for clinical genetic testing. This panel is used frequently in prenatal and adult 
clinical genetics settings, and was selected by this study in order to assess the yield of this panel 
in the Armenian population as compared to other populations from previous studies. A list of the 
genes and conditions included in the ECS panel can be found in Appendix B, as well as 
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information regarding ACOG and ACMG testing recommendations for some of the genes. This 
process was completed separately for each of the batches (25 and 19 samples, respectively). The 
variants were exported for each of the batches as a spreadsheet, and the spreadsheets were 
manipulated to include only the 25 and 19 Armenian samples, respectively. A combined data set 
of the 44 Armenian samples and all variants observed in either or both of the data sets was 
created. Data management to merge the data from the two batches was accomplished using SPSS 
v.25 (IBM Corp., Armonk, NY). Genotypes were excluded from further analysis if they had a 
GQ score of <90, a minor allele frequency (MAF) of the alternate allele of <.35, or if there were 
low or inconsistent quality scores in multiple individuals for the variant. 
 
II.VI. Data Analysis 
 In the annotated data set, variants were assessed based on their clinical significance 
reported in ClinVar. Using the “Clinical Significance” column from ClinVar in the exported 
spreadsheets, variants were examined if they had at least one assertion that was pathogenic or 
likely pathogenic, or if the variant had no associated ClinVar record. These variants were 
subsequently reviewed for additional or updated classifications in ClinVar (April to May, 2019) 
and any newly available assertions were imported into the data set. Variants are included as 
pathogenic or likely pathogenic in this study based on the consensus ClinVar classification (2015 
- May 2019). For the remaining number of no-call variants not reported on ClinVar as of May 
2019, Varsome (Saphetor SA, Lausanne, Switzerland; https://varsome.com/) was accessed 
between April 2019-May 2019 and was used for further analysis. 
Varsome is a free online variant analysis tool which compiles information from more 
than 30 cross-referenced public data resources, including ClinVar, RefSeq, GnomAD 
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exomes/genomes (https://gnomad.broadinstitute.org/), ExAC (http://exac.broadinstitute.org/), 
publications, structural variant tools, and in silico prediction models [Kopanos et al., 2018]. 
Varsome uses ACMG guidelines for variant classification [Richards et al., 2015], in order to 
automatically predict the ACMG classification for each variant, even if the variant is novel 
[Kopanos et al., 2018]. Variants that had an ACMG predicted classification of benign, likely 
benign, or VUS were not included in the list of pathogenic and likely pathogenic variants 
reported in this study. Two variants that were not reported in ClinVar were included as 
pathogenic or likely pathogenic because they had an ACMG predicted classification of 
pathogenic or likely pathogenic in Varsome with the following supporting lines of evidence: 
PVS1 (premature truncation) and PM2 (rarity) [Richards et al., 2015].  
The total number of variants identified in any of the Armenian individuals was quantified 
with SPSS using the merged data set that combined all variants seen in the initial 25 samples, the 
19 samples, or both. The total number of pathogenic and likely pathogenic variants and the 
number of pathogenic and likely pathogenic variants identified in each sample were counted. 
Expanded carrier screening positive rates (ECS-PRs) were calculated in this population when all 
of the 176 conditions were included and also when FMF was excluded. Confidence intervals 
(95% CI) were calculated for each of the carrier frequencies associated with the conditions in 
which there were multiple carriers identified. A 95% confidence interval was also calculated for 
each of the ECS-PRs. Allele frequencies were collected from GnomAD (date accessed May 
2019) for the variants associated with conditions in which there were multiple carriers identified. 
Both the ECS-PRs and the allele frequencies were compared between the findings in this study 
and findings that have previously been reported. 
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III. RESULTS  
III.I. Characterization of Variants and Assessment of Associated Conditions 
This study aimed to characterize the spectrum of genetic variation related to autosomal 
recessive disorders seen in Armenian individuals in a subset of clinically relevant genes. The 
vast majority of the variants reported were missense and synonymous variants. A breakdown of 
how variants were analyzed and classified is displayed in Figure 1.   
The total number of variants present in the genes associated with the ECS panel in the 
VCF file was 2085 (Figure 1; I.I). Of these 2085 variants, 1307 variants were detected in at least 
one of the 44 Armenian individuals (Figure 1; II.I). Therefore, 778 variants were only present in 
the non-Armenian individuals and were omitted from further analyses (Figure 1; II.II). Of the 
1307 variants identified in the Armenian cohort, 913 were annotated as benign, likely benign, 
variant of uncertain significance (VUS), or other according to ClinVar (freeze 2017 09 05) 
(Figure 1; III.II). No further analyses were performed with these variants. These variants are 
included in the list of all other variants called in the VCF files in Appendix A. 
In the 44 individuals, a total of 66 variants had at least one pathogenic or likely 
pathogenic assertion, or had conflicting interpretations of pathogenicity, as annotated by ClinVar 
(freeze 2017 09 05) (Figure 1; III.I). Three of these 66 variants were omitted because of low GQ 
(<90), low MAF (<.35), or inconsistency in the quality of the call across individuals for that 
variant (Figure 1; IV.II). Of the 63 that were evaluated on ClinVar (April to May 2019), 21 
variants were classified as pathogenic or likely pathogenic (Figure 1; V.I). Of the variants that 
initially had at least one pathogenic, likely pathogenic, or conflicting interpretations of 
pathogenicity assertion, 42 were reported as benign, likely benign or VUS based on the 
consensus on ClinVar (Figure 1; V.II).  
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Figure 1. Variant Curation and Carrier Identification Flowchart: The total number of 
variants (I.I) was divided into those in the Armenians (II.I) and those not in the Armenians. III.I, 
III.II, and III.III represent different annotations provided by ClinVar (freeze 2017 09 05). V.I and 
V.III represent variants with a ClinVar (April-May 2019) consensus of pathogenic or likely 
pathogenic or a Varsome pathogenic or likely pathogenic classification (as outlined by ACMG, 
Richards et al., 2015). V.II and V.IV represent variants that were not reported as pathogenic or 
likely pathogenic after checking ClinVar and Varsome. 
 
I.I	  	  Variants	  Called	  in	  the	  VCF	  File	  	  (2085)	  
II.I	  	  Variants	  called	  in	  Armenian	  Individuals	  (1307)	  
III.I	  ClinVar	  2017	  annotation:	  Includes	  at	  least	  one	  pathogenic,	  likely	  pathogenic,	  or	  conFlicting	  interpretation	  (66)	  
IV.I	  Evaluated	  on	  ClinVar	  2019	  (63)	  
V.I	  	  Pathogenic	  or	  Likely	  Pathogenic	  (21)	  
V.II	  Not	  included	  as	  Pathogenic	  (42)	  
IV.II	  Omitted	  due	  to	  GQ<90	  or	  low	  MAF<.35	  (3)	  
III.II	  ClinVar	  2017	  annotation:	  Benign,	  Likely	  Benign,	  Uncertain	  (913)	  
III.III	  No	  ClinVar	  2017	  	  annotation	  (328)	  
IV.III	  Evaluated	  on	  ClinVar	  2019	  and	  Varsome	  	  (313)	  
V.III	  Pathogenic	  or	  Likely	  Pathogenic	  (7)	  
V.IV	  Not	  included	  as	  Pathogenic	  (306)	  
	  IV.IV	  Omitted	  due	  to	  GQ<90	  or	  MAF<.35	  (15)	  	  
II.II	  Variants	  from	  Non-­‐Armenian	  Individuals	  (778)	  
III.IV	  Omitted	  	  (778)	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A total of 328 variants had no annotation from ClinVar (Figure 1; III.III). Fifteen of these 
328 variants were omitted because of low GQ (<90), low MAF (<.35), or inconsistency in the 
quality of the call across individuals for that variant (Figure 1; IV.IV). Of the 313 that were 
reviewed for updated records from ClinVar and Varsome, 7 were identified as pathogenic or 
likely pathogenic variants (Figure 1; V.III). The remaining 306 variants for which there was no 
ClinVar annotation (Figure 1; V.IV) were included in the list of all other variants called in the 
VCF files in Appendix A. All of the pathogenic and likely pathogenic variants (N=28) reported 
in at least one of the Armenian individuals are listed in Table 1. 
Table 1. Pathogenic and Likely Pathogenic Variants Identified in the 44 Individuals 
Gene DNA Sequence Change 
Protein 
Sequence 
Change 
Type of 
Variant Associated Condition 
ACADS c.973C>T p.Arg325Trp Missense Deficiency of butyryl-CoA dehydrogenase 
ALDOB c.448G>C p.Ala150Pro Missense Hereditary fructose intolerance 
ALG6 c.1128-2A>C _ Splice Acceptor 
Congenital disorder of 
glycosylation type 1C 
ASS1 c.470G>A p.Arg157His Missense Citrullinemia, type 1 
ATM c.7671_7674delGTTT p.Phe2558Leufs Deletion Ataxia-telangiectasia syndrome 
CBS c.434C>T p.Pro145Leu Missense Homocystinuria, pyridoxine responsive 
CFTR c.3154T>G p.Phe1052Val Missense Cystic Fibrosis 
DHCR7  c.964-1G>C _ Splice Acceptor 
Smith-Lemli-Opitz 
syndrome 
FAH c.554-1G>T _ Splice Acceptor Tyrosinemia, type 1 
GALC c.956A>G p.Tyr319Cys Missense Krabbe disease 
GALT c.881T>A p.Phe294Tyr Missense Galactosemia 
GJB2 c.35delG p.Gly12Valfs Deletion GJB2-related Non-syndromic Hearing Loss 
HEXA c.1511G>A p.Arg504His Missense Tay-Sachs disease 
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IDUA c.510_511insAGTTCCA p.His171Serfs Insertion Mucopolysaccharidosis type I 
LAMA2 c.2451-2A>G _ Splice Acceptor 
LAMA2-related 
muscular dystrophy 
MEFV c.2282G>A p.Arg761His Missense Familial Mediterrannean Fever 
MEFV c.2177T>C p.Val726Ala Missense Familial Mediterrannean Fever 
MEFV c.2080A>G p.Met694Val Missense Familial Mediterrannean Fever 
MEFV c.2040G>C p.Met680Ile Missense Familial Mediterrannean Fever 
NPC1 c.352_353delAG p.Gln119Valfs Deletion Niemann-Pick disease type C 
PAH c.782G>A p.Arg261Gln Missense Phenylketonuria 
PAH c.842C>T p.Pro281Leu Missense Phenylketonuria 
PAH c.898G>T p.Ala300Ser Missense Phenylketonuria 
PAH c.1208C>T p.Ala403Val Missense Phenylketonuria 
PKHD1 c.4870C>T p.Arg1624Trp Missense 
PKHD1-Related 
Autosomal Recessive 
Polycystic Kidney 
Disease 
PMM2 c.367C>T p.Arg123Ter Nonsense Congenital Disorder of Glycosylation, Type Ia 
PMM2 c.422G>A p.Arg141His Missense Congenital Disorder of Glycosylation, Type Ia 
SLC26A2 c.235C>T p.Gln79Ter Nonsense 
Sulfate Transporter-
Related 
Osteochondrodysplasia 
 
The genes and conditions for which at least one individual in this study was found to be a 
carrier of a pathogenic or likely pathogenic variant are listed in Table 1. Individuals were carriers 
of pathogenic or likely pathogenic variants in genes related to 21 conditions. There were four 
conditions for which there were multiple carriers, as shown in Table 3. These were cystic 
fibrosis, familial Mediterranean fever, phenylketonuria, and congenital disorder of glycosylation, 
type Ia. Two different individuals (5%, 95% CI: <0.1%-11.4%) were carriers for the same CFTR 
variant, c.3154T>G.  
 
29 	  
Table 2. Conditions for which Multiple Carriers were Identified 
Gene 
DNA 
Sequence 
Change 
Protein 
Sequence 
Change 
Associated 
Condition 
Number of 
Carriers 
CFTR c.3154T>G p.Phe1052Val Cystic Fibrosis 2 
MEFV 
c.2040G>C 
c.2080A>G 
c.2177T>C 
c.2282G>A 
p.Met680Ile 
p.Met694Val 
p.Val726Ala 
p.Arg761His 
Familial 
Mediterranean 
Fever 
1                                    
2                                     
3                                        
1 
PAH 
c.782G>A 
c.898G>T 
c.1208C>T 
c.842C>T 
p.Arg261Gln 
p.Ala300Ser 
p.Ala403Val 
p.Pro218Leu 
Phenylketonuria 
1                            
1                                
1                                    
1 
PMM2 c.367C>T c.422G>A 
p.Arg123Ter 
p.Arg141His 
Congenital 
Disorder of 
Glycosylation, 
Type Ia 
1                         
1 
 
There were a total of seven carriers (16%, 95% CI: 5.2%-26.8%) for pathogenic variant 
associated with FMF in this healthy Armenian cohort. Four different MEFV variants were seen 
in the seven individuals. Two individuals were carriers for c.2080A>G, and three individuals 
were carriers for c.2177T>C. In addition to the four known pathogenic variants, five individuals 
were carriers for the MEFV c.442G>C variant (Appendix A), which was excluded from further 
analysis due to uncertain clinical significance [Shohat and Halpern, 2011]. Four individuals (9%, 
95% CI: 0.5%-17.5%) were carriers for four distinct PAH pathogenic variants in this cohort. 
Two individuals (5%, 95% CI: <0.1%-11.4%) were carrier for two distinct PMM2 pathogenic 
variants in this cohort.  
The allele frequencies from GnomAD are reported for the variants in the conditions in 
which there were multiple carriers identified (Tables 3, 4, 5).  
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Table 3. GnomAD Allele Frequencies for MEFV Pathogenic Variants 
 
	  
MEFV 
c.2282G>A 
p.Arg761His 
MEFV 
c.2177T>C 
p.Val726Ala 
MEFV 
c.2080A>G 
p.Met694Val 
MEFV 
c.2040G>C 
p.Met680Ile 
Ashkenazi 
Jewish 
0 / 10370                      
(0%) 
407 / 10368                 
(3.9%) 
0 / 10370                        
(0%) 
0 / 10080                              
(0%) 
European 
(non-
Finnish) 
10 / 129148                          
(0.008%) 
115 / 129180                      
(0.09%) 
59 / 129184                      
(0.05%) 
2 / 113758                            
(0.002%) 
European 
(Finnish) 
0 / 25116                         
(0%) 
0 / 25122                         
(0%) 
0 / 25120                       
(0%) 
0 / 21644                              
(0%) 
Latino 3 / 35438                      (0.008%) 
8 / 35440                           
(0.02%) 
9 / 35438                    
(0.03%) 
0 / 34588                              
(0%) 
South 
Asian 
4 / 30616                         
(0.01%) 
3 / 30616                        
(0.01%) 
0 / 30616                        
(0%) 
0 / 30616                              
(0%) 
East Asian 38 / 19954                         (0.2%) 
0 / 19950                         
(0%) 
0 / 19954                        
(0%) 
0 / 18394                              
(0%) 
African 2 / 24964                      (0.008%) 
0 / 24968                         
(0%) 
2 / 24968                       
(0.008%) 
0 / 16256                              
(0%) 
Other 1 / 7222                         (0.01%) 
28 / 7226                            
(0.4%) 
7 / 7226                         
(0.1%) 
0 / 6138                              
(0%) 
Total 58 / 282828                     (0.02%) 
561 / 282870                           
(0.2%) 
77 / 282876                        
(0.03%) 
2 / 251474                              
(0.0008%) 
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Table 4. GnomAD Allele Frequencies for PAH Pathogenic Variants 
	  
PAH 
c.782G>A 
PAH 
c.842C>T 
PAH 
c.898G>T 
PAH 
c.1208C>T 
Ashkenazi 
Jewish 
3 / 10368                   
(0.3%) 
0 / 10366                              
(0%) 
71 / 10350                     
(0.7%) 
53 / 10368                  
(0.5%) 
European 
(non-
Finnish) 
46 / 129078                 
(0.04%)  
26 / 128978                            
(0.02%) 
58 / 128846                         
(0.05%) 
96 / 129168                   
(0.07%) 
European 
(Finnish) 
0 / 25124               
(0%) 
2 / 25124                              
(0.008%) 
0 / 25100                   
(0%) 
0 / 25124                        
(0%) 
Latino 4 / 35432                 (0.01%) 
0 / 35434                              
(0%) 
3 / 35408                  
(0.008%) 
8 / 35394                      
(0.02%) 
South 
Asian 
0 / 30616               
(0%) 
0 / 30616                              
(0%) 
15 / 30608                   
(0.05%) 
1 / 30614                     
(0.003%) 
East Asian 2 / 19948                      (0.01%) 
0 / 19952                              
(0%) 
0 / 19936                   
(0%) 
0 / 19950                        
(0%) 
African 1 / 24960                     (0.004%) 
1 / 24964                              
(0.004%) 
0 / 24948                   
(0%) 
3 / 24958                         
(0.01%) 
Other 5 / 7222                     (0.07%) 
0 / 7218                              
(0%) 
5 / 7214                    
(0.07%) 
3 / 7228                     
(0.04%) 
Total 61 / 282748                      (0.02%) 
2 / 251474                              
(0.0008%) 
152 / 282410                 
(0.05%) 
164 / 282804                        
(0.06%) 
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Table 5. GnomAD Allele Frequencies for CFTR and PMM2 Pathogenic Variants 
 
CFTR 
c.3154T>G 
PMM2 
c.367C>T 
PMM2 
c.422G>A 
Ashkenazi 
Jewish 
21 / 10348                 
(0.2%) 
0 / 9374                         
(0%) 
71 / 9376                              
(0.8%) 
European 
(non-
Finnish) 
117 / 128594             
(0.09%) 
3 / 93654                        
(0.003%) 
511 / 94084                         
(0.5%) 
European 
(Finnish) 
6 / 25038                   
(0.02%) 
0 / 20984                        
(0%) 
177 / 21196                               
(0.8%) 
Latino 22 / 35218                  (0.06%) 
3 / 30562                      
(0.01%) 
64 / 30676                          
(0.2%) 
South 
Asian 
2 / 30532                
(0.007%) 
0 / 25432                        
(0%) 
24 / 25492                    
(0.09%) 
East 
Asian 
0 / 19924                    
(0%) 
0 / 16514                           
(0%) 
2 / 16632                          
(0.01%) 
African 0 / 24932                        (0%) 
0 / 20560                         
(0%) 
15 / 20700                         
(0.07%) 
Other 9 / 7174                  (0.1%) 
1 / 6152                     
(0.02%) 
27 / 6220                         
(0.4%) 
Total 177 / 281760           (0.06%) 
7 / 223232                        
(0.003%) 
891 / 224376                        
(0.4%) 
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III.II. Expanded Carrier Screening Positive Rates 
Expanded carrier screening positive rates (ECS-PRs) were calculated for this cohort in 
order to estimate the proportion of individuals that would be identified as a carrier for at least 
one of the conditions on a commonly used expanded carrier screening panel in the clinical 
setting (Table 6). The ECS-PR for when all of the conditions on the ECS panel were included 
was 52% (95% CI: 37%-67%). 
Table 6. Expanded carrier screening positive rates (ECS-PRs) 
 
One 
Condition 
Two 
Conditions 
At Least 
One 
Condition 
N 14 9 23 
% 32% 20% 52% 
 
 This study also calculated ECS-PRs when FMF was excluded from analyses (Table 7). 
The ECS-PR for when FMF was excluded was 48% (95% CI: 33%-63%). 
Table 7. Expanded carrier screening positive rates (ECS-PRs) when FMF is excluded 
 
One 
Condition 
Two 
Conditions 
At Least One 
Condition 
N 17 4 21 
% 39% 9% 48% 
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IV. DISCUSSION 
 The two overarching aims of this study were to gather additional information about 
genetic variation in individuals of Armenian ancestry and to provide clinicians, such as genetic 
counselors, with a better understanding of considerations to make when counseling individuals 
of Armenian ancestry. Additional studies are highly recommended in order to increase breadth 
and generalizability of the results to the Armenian population as a whole. 
 
IV.I. Increasing Knowledge of Human Genetic Variation 
As the first study of its kind in the Armenian population, this project aimed to identify 
and categorize pathogenic and likely pathogenic variants found in the genes associated with 176 
conditions that are commonly tested for in expanded carrier screening. While this is a small 
cohort study, this information will hopefully help build to the general knowledge about genetic 
variants observed in Armenians and humans in general.  
Previous studies have shown that the carrier frequency of familial Mediterranean fever in 
Armenians is approximately 1 in 7 [Rogers et al., 1989]. The carrier frequency of 16% found in 
this cohort is comparable to reported frequencies in previous studies [Rogers et al., 1989; Ong et 
al., 2013].  
The MEFV variants that were identified in the individuals in this cohort have all been 
reported in Armenian individuals in previous studies [Ong et al., 2013]. Three out of four of the 
pathogenic changes that were found, c.2080A>G, c.2177T>C, and c.2040G>C, are some of the 
most common MEFV changes seen in individuals of Mediterranean and Middle Eastern ancestry 
[Shohat and Halpern, 2011]. The c.2080A>G variant was seen in two of the individuals in this 
cohort, and it is seen most commonly in individuals of European (non-Finnish; NFE) and Latino 
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ancestries (GnomAD). More specifically, studies have shown that this variant is seen at a higher 
frequency in northern European, Iranian, and Azeri Turkish populations [Shohat and Halpern, 
2011]. A retrospective study performed at UCLA in individuals with FMF, many of whom were 
Armenian-Americans, found a high frequency of c.2080A>G homozygotes in Armenians 
(12/34), as well as a significant number of c.2080A>G compound heterozygotes (17/34) [Ong et 
al., 2013]. This was significantly higher than the number of c.2080A>G carriers seen in other 
ethnicities. Individuals with the c.2080A>G variant have been found to be at a much higher risk 
for AA amyloidosis, and therefore a poorer clinical outcome. Homozygous individuals such as 
these would have likely been missed in this study during recruitment, since criteria for 
enrollment in the study required that the individuals be healthy and greater than 60 years old. 
Another MEFV variant, c.2177T>C was identified in three individuals in this cohort and is seen 
at a higher frequency in individuals of Ashkenazi Jewish ancestry (GnomAD). The c.2282G>A 
variant was seen at the highest frequency in individuals of East Asian ancestry, and the 
c.2040G>C variant was only reported in individuals of NFE ancestry (GnomAD). FMF patients 
with these three pathogenic variants have been shown to be less likely to develop AA 
amyloidosis, and may be associated with a milder clinical phenotype as compared to c.2080A>G 
[Ong et al., 2013]. In many cases, knowledge of a person’s genotype is actually quite important 
for determining prognosis and prevention of life-threatening complications that can arise from 
the disease. 
In this cohort, five individuals were carriers for the VUS, c.442G>C, which is also 
considered to be a founder variant in individuals of Mediterranean ancestry and has been seen in 
individuals who have FMF [Shohat and Halpern, 2011; Ong et al., 2013]. Ong et al. reported that 
the c.442G>C variant has also been seen in individuals of Asian ancestry, some of whom were 
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affected individuals in a homozygous or even heterozygous state. There is a single assertion 
submitted in ClinVar from the year 2000 which reports this variant as pathogenic when found in 
a haplotype block with another variant, c.2082G>A [Booth et al., 2000]. Conversely, many 
laboratories on ClinVar still classify this variant as benign or VUS. Therefore, the assertion 
provided by a single source was not sufficient for this variant to be included as pathogenic in this 
study. If this study had included c.442G>C as a pathogenic variant as in Ong et al., there would 
have been a total of 12 (27%) carriers of pathogenic MEFV variants instead of seven (16%). 
Although this study did not include the c.442G>C variant as a pathogenic variant, some studies 
continue to assert that it may play a role in disease development [Ong et al., 2013; Booth et al., 
2000]. Thus, this variant could benefit from further analyses in order to determine a consensus 
regarding its classification. 
In addition to the four MEFV variants, population frequencies were assessed for the 
variants that were associated with other conditions in which there were multiple carriers 
identified in this cohort. The CFTR variant that was identified in two individuals of this cohort, 
c.3154T>G, is seen at the highest frequencies in individuals of Ashkenazi Jewish and NFE 
ancestries. Of the two PMM2 variants, the c.367C>T variant is more rare than the c.422G>A 
variant. The c.422G>A variant is seen at higher frequencies in European (Finnish), Ashkenazi 
Jewish, and NFE ancestries. Three of the four PAH variants seen in this cohort were seen at the 
highest frequencies in individuals of Ashkenazi Jewish and NFE ancestries.  
It is known that the incidence of PKU varies greatly across different populations (1:4,000 
to 1:2,600 in Turkey, 1:4,500 in Ireland, 1:10,000 in Northern Europeans, 1:200,000 in Finland) 
[Kostandyan et al., 2011]. However, as was noted in Kostandyan et al., the incidence among 
Armenians is unknown. Their study estimated the incidence could be 1 in 8,300, which would 
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correspond to a carrier frequency of 1 in 46 (2.2%), although they did believe this was an 
underestimate [Kostandyan et al., 2011]. In the current study, four out of 44 individuals (9%) 
were found to be carriers for PKU. This frequency is quite high compared to reported 
frequencies in other populations, such as in Turkish individuals who have one of the highest 
reported carrier frequencies (1 in 26; 3.8%) for the condition [Özalp et al., 2001; Kostandyan et 
al., 2011]. However, given the small sample size, the 95% confidence interval is wide, and this 
may be an overestimate of the true carrier frequency. Regardless, this finding does add to what 
limited research has been done in this population to date. Three of the four PAH pathogenic 
variants seen in this cohort, c.782G>A, c.842C>T, and c.1208C>T, were also observed in 
Kostandyan et al., and the c.782G>A and c.842C>T were two of the most common variants seen. 
The fourth variant present in this cohort, c. 898G>T, was not seen in the previous study. Perhaps 
the greatest benefit of these analyses is the impact that this information could have on patient 
care in the clinical setting. If the carrier frequency for PKU in Armenians in the general 
population is as high as what was seen in this cohort, it will be important to continue to expand 
public health initiatives in Armenia. Knowledge of the carrier frequency may help to motivate 
health professionals. Armenia initiated its neonatal screening program for PKU on April 15, 
2008 [Kostandyan et al., 2011]. However, there are no publications that highlight how uniformly 
neonatal screening is carried out in Armenia. As medical advancements in the country continue 
to be made, particularly outside of major metropolitan areas, it will be of the utmost importance 
to grow public health initiatives and to improve the overall quality of medical care for 
individuals with rare genetic disorders.  In addition to newborn screening, it will be important to 
also begin offering expanded carrier screening to patients in order to provide parents with more 
options regarding family planning and the health of their children. 
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IV.II. Utility of Expanded Carrier Screening Across Populations 
 This study explored the value of expanded carrier screening in an underserved 
population. While many individuals in this cohort would have been identified as FMF carriers 
had they had ECS performed clinically, it is noteworthy that a great many more were identified 
as carriers for conditions other than FMF. Only two of 23 carrier individuals were carriers for 
FMF alone. Multiple studies have been completed in individuals of different ethnicities and 
populations that have shown a wide range of results regarding the percentage of individuals that 
are identified as a carrier after undergoing ECS. Two previous studies performed in separate 
ethnically diverse populations have shown that approximately 25-30% of individuals who 
underwent expanded carrier screening were identified as a carrier for at least one condition 
[Peyser et al., 2018; Lazarin et al., 2013]. However, both of these studies utilized targeted 
genotyping of about 400 common variants associated with approximately 100 genetic conditions 
[Peyser et al., 2018; Lazarin et al., 2013]. Another large study in Barcelona that performed 
targeted genotyping as well as NGS on a portion of the genes in the ECS panel reported that 56% 
of the individuals in their cohort were carriers for at least one condition [Abulí et al., 2016]. 
Estimates of the yield of ECS have been reported to be as high as 84% in another Spanish study, 
which was completed in a population of gamete donors and couples seeking assisted 
reproductive technologies (ART) in Valencia [Martin et al., 2015]. The testing methodology that 
was used in Martin et al. involved NGS for 549 autosomal and X-linked recessive genes, making 
it the largest ECS screen of these four studies [Martin et al., 2015]. Therefore, studies have 
shown a large range in the approximations of the yield of different ECS panels. The ECS-PRs 
calculated in this study are within the range of those reported in the literature, given the large 
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confidence intervals on this estimate. [Peyser et al., 2018; Lazarin et al., 2013; Abulí et al., 2016; 
Martin et al., 2015]. Additionally, the ECS-PR (52%) in this study was not only due to the high 
frequency of FMF in this population, since the ECS-PR was nearly as high (48%) when FMF 
was not included in the calculation. However, we recognize that the small cohort size may affect 
the accuracy of the ECS-PRs, as demonstrated by the wide confidence intervals. 
These findings provide support for the utility of expanded carrier screening in Armenian 
individuals, since indeed many of the individuals whose samples were sequenced as part of this 
study were identified to be carriers for a variety of different conditions. There were three 
conditions other than FMF in which there were multiple individuals identified as carriers: cystic 
fibrosis, PKU, and congenital disorder of glycosylation, type 1a. If these individuals had only 
been tested for FMF based on their high-risk ethnicity status, only seven individuals would have 
been identified as carriers, resulting in 16 missed carriers that would have been identified by 
ECS.  
The results of this study may encourage the growth and implementation of expanded 
carrier screening in Armenia, since currently expanded carrier screening is not routinely offered 
to individuals in Armenia. When designing expanded carrier screening panels, it would be 
prudent for laboratories to strive to have the highest detection rate for conditions, rather than 
having more conditions, in order to provide patients with the highest possible negative predictive 
values (NPV) [Beauchamp et al., 2018]. While some experts in the field have suggested that 
FMF not be included on ECS panels since it does not typically have a severe outcome in affected 
individuals, carrier testing for FMF can be worthwhile in a number of Non-European ancestries, 
such as Armenians, Iranians, and Northern-African Jews, since the condition can be severe in 
some cases and has management guidelines for treatment of affected individuals [Romero et al., 
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2017; Shohat and Halpern, 2011]. These ethnicities have a higher carrier frequency for FMF than 
many other conditions that are included on nearly all ECS panels, such as cystic fibrosis [Shohat 
and Halpern, 2011; Rink et al., 2017]. As individuals from a variety of ethnic backgrounds 
consider having expanded carrier screening, it will be important for genetic counselors and other 
medical professionals to discuss the specific conditions on an ECS panel that have the highest a 
priori risk for any given individual, whether based on ethnicity or family history. 
 
IV.III. Genetic Counseling Considerations 
 Genetic counseling is a crucial component in the process of obtaining informed consent 
and ordering genetic testing, such as an ECS panel. It is very important for genetic counselors to 
have an understanding about their clients’ cultural background, in addition to their genetic risks, 
in order to build good rapport with and instill trust in their patients. As an ethnic population that 
experienced great trauma in the early 20th century and has taken over a century to recover from 
these events, it is the job of the genetic counselor to be aware of this history and to be cautious 
with how genetic risk information is presented. As has been seen with other ethnicities that have 
undergone such events, many individuals in the population may be particularly sensitive 
regarding any possible genetic differences they may have, even though it is known that 
individuals of all ancestries carry pathogenic genetic variants. Special care should be taken to 
emphasize that all individuals are carriers for certain genetic conditions, and that individuals 
have no choice regarding the genetic information that they inherit or that they pass down to their 
children. As always, it is also important to stress the possibility of variants of uncertain 
significance, particularly since Armenians remain an understudied population. It would be 
helpful to provide Armenian individuals with an estimate of the chance that they will be found to 
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be a carrier for at least one condition on an ECS panel, such as the one used for gene selection in 
this study. Although the exact ECS-PR (52%) is only an estimate based on a small sample of 
Armenian individuals, genetic counselors and other health professionals may consider using an 
estimate based on previous studies in other populations, and noting that the chance of receiving a 
positive result may be a little higher in the Armenian population. 
 
IV.IV. Limitations 
 The following limitations were present in this study. First, given the small cohort size, 
one cannot make generalizations regarding carrier frequencies for the majority of the conditions 
screened. This study methodology may have under-sampled homozygotes, and so this sample 
would be expected to result in an underestimate of the frequency of pathogenic and likely 
pathogenic alleles, although this would not be expected to significantly impact the carrier 
frequencies for rare conditions since homozygotes are rare in the population. However, for a 
common condition like FMF, the under-sampling of homozygotes could theoretically impact 
estimates of the carrier frequency.  
The type of testing performed on the individuals in this study presented a different set of 
limitations. Although exome sequencing provided a wide breadth of coverage for genes to study, 
it would not have detected all of the types of variants that may have been picked up on a 
specially designed expanded carrier screen. The majority of the genes selected for this study are 
screened using full gene sequencing and copy number analysis. While this exome sequencing 
assay was able to detect sequencing changes as well as small insertions and deletions, it could 
not detect large copy number changes. Additionally, some of the genes on the panel require 
additional testing methodologies in order to detect variants commonly seen in the condition and 
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avoid calling errors, as described in Beauchamp et al. [Beauchamp et al., 2018]. A list of all of 
the conditions in the ECS panel is included in Appendix B, which also indicates whether a gene 
typically requires supplemental analyses for specific variant detection beyond standard NGS. For 
example, analyses performed for alpha thalassemia include analysis of homologous regions and 
13 common variants, including deletions that are seen more commonly in individuals of Asian 
ancestry. Therefore, exome sequencing would have had a very low yield for pathogenic changes 
related to alpha thalassemia, since sequence changes are not the most common cause for the 
condition. Spinal muscular atrophy is another such condition in which targeted carrier screening 
utilizes non-NGS technology. For this condition, the primary screening assay is for copy number 
variants, such as deletions, which also would not have been detected by exome sequencing. 
Lastly, some of the genes on the panel such as CYP21A2, which is associated with congenital 
adrenal hyperplasia, are notoriously difficult to sequence due to obstacles such as pseudogenes 
[Xu et al., 2013; Beauchamp et al., 2018]. A clinically utilized expanded carrier screen would 
likely account for these difficulties and would perform further analyses for completion and to 
ensure proper coverage; however, this exome sequencing assay did not. Indeed, at least one 
CYP21A2 variant was identified in this cohort that was reported as pathogenic on ClinVar, but 
had consistently low genotype quality scores in the individuals sequenced in this study, possibly 
due to pseudogene interference, and was therefore omitted from the results.  
 
IV.V. Conclusions and Recommendations for Future Studies  
This study reported information regarding pathogenic, likely pathogenic, and other 
variants seen in this population, which can provide a starting point for additional studies. Further 
analysis of the variants identified in this cohort that did not have any ClinVar annotation may be 
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valuable. It may also be instructive to compare what the anticipated performance would be for a 
larger ECS panel as compared to the one used in this study. Variation in the 59 genes currently 
recommended by the ACMG for reporting of secondary findings [Kalia et al., 2017] could also 
be evaluated for the Armenian population, although this particular sample would not be the best 
cohort for such a study. It may be less informative to study autosomal dominant conditions in a 
group of healthy, older individuals since individuals with high and moderately penetrant 
pathogenic variants may have a reduced life-span or not be considered healthy.  
If the ArmGenia project or another research group were able to collect additional samples 
of affected individuals for various conditions, such as cancer, then this would allow for further 
investigation of various genetic conditions in Armenian individuals. In general, many more 
studies need to be done in Armenian individuals in order to provide greater insights for public 
health initiatives both in the U.S., where there is a relatively large Armenian population, and in 
Armenia, where public health is beginning to make new and important advancements. 
This study reaffirms that there are other conditions in addition to FMF that Armenian 
individuals should be screened for in order to provide accurate reproductive risks to couples. 
This study provides evidence in support of expanded carrier screening in Armenian individuals 
as compared to targeted testing for FMF only. Results of this study may help to improve genetic 
counseling provided to Armenian individuals, particularly in prenatal and pre-conceptional 
settings, and promote diversity and equity in the field of genetics to improve the overall quality 
of services for providers and patients alike. 
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APPENDIX A: List of All Other Variants Called in this Cohort in the VCF Files 
Gene Variant Gene  Variant  
ABCC8 c.4714G>A LAMA2 c.8124T>A 
ABCC8 c.4105G>T LAMA3 c.2225G>A 
ABCC8 c.3819G>A LAMA3 c.3980G>A 
ABCC8 c.2485C>T LAMA3 c.1217G>A 
ABCC8 c.2277C>T LAMA3 c.373C>T 
ABCC8 c.1947G>A LAMA3 c.661A>G 
ABCC8 c.330C>T LAMA3 c.2764G>A 
ABCC8 c.207T>C LAMA3 c.2809C>T 
ABCD1 c.2019C>T LAMA3 c.342T>C 
ACADM c.127G>A LAMA3 c.695G>A 
ACADM c.416A>G LAMA3 c.1806G>A 
ACADM c.286+178G>A LAMA3 c.2387C>A 
ACADM c.1161A>G LAMA3 c.2901T>C 
ACADS c.1108A>G LAMA3 c.3066C>G 
ACADS c.321T>C LAMA3 c.3617T>C 
ACADS c.360C>T LAMA3 c.3622C>A 
ACADS c.625-99T>C LAMA3 c.4110G>A 
ACADS c.625G>A LAMA3 c.4260G>C 
ACADS c.990C>T LAMA3 c.4530C>T 
ACADVL c.99C>A LAMA3 c.110T>G 
ACADVL c.957G>A LAMA3 c.495C>T 
ACADVL c.1824C>T LAMA3 c.1320C>G 
ADA c.508A>G LAMA3 c.3618C>A 
ADA c.534A>G LAMA3 c.3673A>G 
ADA c.390G>A LAMA3 c.3904C>T 
ADA c.239A>G LAMB3 c.3404G>A 
ADA c.36G>A LAMB3 c.773G>A 
AGA c.34G>T LAMB3 c.1873C>T 
AGA c.446C>G LAMB3 c.927C>T 
AGL c.686A>G LAMB3 c.417C>T 
AGL c.461G>A LAMB3 c.3432A>G 
AGL c.4331A>G LAMB3 c.2777C>A 
AGL c.4575T>A LAMB3 c.2673A>G 
AGL c.894C>T LAMB3 c.2554A>T 
AGL c.3199C>T LAMB3 c.2124T>C 
AGL c.3343G>A LAMB3 c.2069A>G 
AGXT c.332G>A LAMB3 c.1764T>C 
AGXT c.1030G>A LAMB3 c.1716T>C 
AGXT c.32C>T LAMB3 c.1579G>A 
AGXT c.264C>T LAMB3 c.1149G>A 
AGXT c.654G>A LAMB3 c.1051G>A 
49 	  
AGXT c.1020A>G LAMB3 c.1015T>C 
AIRE c.329G>A LAMB3 c.541A>G 
AIRE c.588C>T LAMB3 c.384C>T 
AIRE c.681C>T LAMB3 c.291A>C 
AIRE c.834C>G LAMB3 c.138C>T 
AIRE c.1197T>C LAMC2 c.566G>T 
AIRE c.1578T>C LAMC2 c.1899G>C 
ALDH3A2 c.328G>A LAMC2 c.2387C>T 
ALDH3A2 c.1446A>T LAMC2 c.344G>A 
ALG6 c.482A>G LAMC2 c.3448C>T 
ALG6 c.727G>A LAMC2 c.3546A>G 
ALG6 c.1323T>C LAMC2 c.297C>T 
ALG6 c.391T>C LAMC2 c.371C>T 
ALG6 c.911C>T LAMC2 c.483C>T 
ALMS1 c.281C>T LAMC2 c.741C>A 
ALMS1 c.1868A>G LAMC2 c.798T>G 
ALMS1 c.3392A>G LAMC2 c.2198G>C 
ALMS1 c.7089G>A LAMC2 c.2688G>A 
ALMS1 c.9457A>T LIPA c.67G>A 
ALMS1 c.12001C>T LIPA c.46A>C 
ALMS1 c.1267G>A LRFN4 c.960G>A 
ALMS1 c.1571_1573dupCTC LRFN4 c.1019T>C 
ALMS1 c.4948G>A LRPPRC c.2481A>G 
ALMS1 c.4993T>G LRPPRC c.2562A>G 
ALMS1 c.10863A>G LRPPRC c.1068A>G 
ALMS1 c.1174C>T LRPPRC c.246G>A 
ALMS1 c.2012T>G MAN2B1 c.1521G>T 
ALMS1 c.2187C>T MAN2B1 c.1068C>G 
ALMS1 c.4176A>G MAN2B1 c.922C>T 
ALMS1 c.4241G>C MAN2B1 c.2310C>T 
ALMS1 c.5623A>G MAN2B1 c.1437G>T 
ALMS1 c.6209T>C MAN2B1 c.1441G>T 
ALMS1 c.6299C>T MAN2B1 c.1238A>G 
ALMS1 c.6333T>A MAN2B1 c.1010G>A 
ALMS1 c.6851G>C MAN2B1 c.935C>T 
ALMS1 c.7721G>A MAN2B1 c.832C>G 
ALMS1 c.8014G>C MCOLN1 c.966A>C 
ALMS1 c.8478G>T MCOLN1 c.984C>T 
ALMS1 c.8567A>G MEFV c.2118G>A 
ALMS1 c.9558C>T MEFV c.1760-5C>T 
ALMS1 c.12086G>A MEFV c.1518C>T 
ALMS1 c.12172C>T MEFV c.1421_1422insACA 
ALPL c.455G>A MEFV c.443A>T 
ALPL c.787T>C MEFV c.1764G>A 
50 	  
ALPL c.876A>G MEFV c.1760-30T>A 
ALPL c.1565T>C MEFV c.1530T>C 
AMT c.354G>A MEFV c.1503C>T 
AMT c.954G>A MEFV c.1428A>G 
AMT c.631G>A MEFV c.1422G>A 
ARG1,MED23 c.270C>T MEFV c.1223G>A 
ARSA c.1442G>A MEFV c.1105C>T 
ARSA c.1149C>T MEFV c.942C>T 
ARSA c.636C>T MEFV c.442G>C 
ARSA c.1493G>A MEFV c.414A>G 
ARSA c.1178C>G MEFV c.306T>C 
ARSA c.1055A>G MESP2 c.803A>T 
ARSA c.1002C>T MKS1 c.1349T>C 
ARSA c.585G>T MKS1 c.404C>A 
ARSA c.459C>T MKS1 c.1671G>C 
ASL c.392C>T MLC1 c.279G>A 
ASPA c.230A>G MLC1 c.597A>G 
ASPA c.693C>T MLC1 c.594C>T 
ASS1 c.1211G>A MLC1 c.512G>T 
ASS1 c.501C>T MMAA c.747G>A 
ASS1 c.876T>C MMAA c.1089G>C 
ATM c.2119T>C MMAB c.398C>T 
ATM c.3277A>G MMAB c.716T>A 
ATM c.4101C>T MMACHC c.641G>A 
ATM c.1744T>C MMACHC c.78C>A 
ATM c.3161C>G MMACHC c.182G>A 
ATM c.4578C>T MMACHC c.766_771delGCCCCC 
ATM c.5557G>A MMACHC c.321G>A 
ATP7A c.2205T>A MPI c.684C>T 
ATP7A c.4356G>C MPI c.1131A>G 
ATP7A c.2299G>C MUT c.1629C>T 
AXDND1 c.3032-3141G>A MUT c.1342G>A 
BBS1 c.24T>C MUT c.2011A>G 
BBS1 c.1634A>G MUT c.1991C>T 
BBS1 c.378G>A MUT c.1595G>A 
BBS10 c.1970C>T MUT c.1495G>A 
BBS10 c.1631A>G MUT c.636G>A 
BBS10 c.1616C>T MYO7A c.1606G>A 
BBS12 c.69G>A MYO7A c.1872G>A 
BBS12 c.116T>C MYO7A c.2886G>C 
BBS12 c.1782A>G MYO7A c.4074C>T 
BBS12 c.1157G>A MYO7A c.4742C>G 
BBS12 c.1380G>C MYO7A c.6203T>G 
BBS12 c.1398C>T MYO7A c.6246C>T 
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BBS12 c.1399G>A MYO7A c.895G>A 
BBS12 c.1410C>T MYO7A c.4577G>A 
BBS12 c.1872A>G MYO7A c.4697C>T 
BBS2 c.98C>A MYO7A c.5487C>T 
BBS2 c.740T>G MYO7A c.47T>C 
BBS2 c.566G>A MYO7A c.288G>A 
BBS2 c.367A>G MYO7A c.468C>T 
BBS2 c.209G>A MYO7A c.510G>A 
BCKDHA c.34C>A MYO7A c.783T>C 
BCKDHA c.116C>A MYO7A c.4755C>T 
BCKDHA c.452C>T MYO7A c.4996A>T 
BCKDHA c.972C>T MYO7A c.5156A>G 
BCKDHA c.1221A>G MYO7A c.5715A>G 
BCKDHB c.1069A>G MYO7A c.6240C>T 
BCKDHB c.987C>T MYO7A c.6318G>A 
BCS1L c.64C>T MYO7A c.6519C>T 
BCS1L c.201C>T NAGLU c.2209C>G 
BCS1L c.628G>A NAGLU c.2209C>G 
BCS1L c.996C>T NAGLU c.1435G>A 
BCS1L c.1017T>C NAGLU c.2157G>A 
BLM c.2268A>G NAGLU c.423T>C 
BLM c.2119C>T NAGLU :c.2209C>A 
BLM c.1122T>C NBN c.2016A>G 
BLM c.1722A>G NBN c.1197T>C 
BLM c.2603C>T NBN c.102G>A 
BLM c.3102G>A NEB c.24220G>T 
BLM c.3531C>A NEB c.22222C>T 
BLM c.3945C>T NEB c.22068A>G 
BLM c.3961G>A NEB c.21487T>C 
CAPN3 c.1290A>G NEB c.21044C>G 
CAPN3 c.1813G>C NEB c.19705A>C 
CAPN3 c.96T>C NEB c.18555G>A 
CAPN3 c.318C>T NEB c.18431A>G 
CAPN3 c.606T>C NEB c.9346G>A 
CAPN3 c.706G>A NEB c.8519A>G 
CBS c.133C>T NEB c.6159G>A 
CBS c.833T>C NEB c.5987C>A 
CBS c.699C>T NEB c.5680A>G 
CDKL5 c.2714-1385A>G NEB c.3416C>T 
CFTR c.224G>A NEB c.877C>T 
CFTR c.1516A>G NEB c.25472C>T 
CFTR c.2991G>C NEB c.22500C>T 
CFTR c.1001G>A NEB c.22075A>C 
CFTR c.1163C>T NEB c.21825C>T 
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CFTR c.1251C>A NEB c.20078C>T 
CFTR c.3897A>G NEB c.11729A>G 
CFTR c.4025G>T NEB c.11148G>C 
CFTR c.443T>C NEB c.10005G>A 
CFTR c.1408G>A NEB c.9467T>A 
CFTR c.1727G>C NEB c.7343G>A 
CFTR c.2002C>T NEB c.5633T>A 
CFTR c.2562T>G NEB c.5420C>T 
CFTR c.3870A>G NEB c.3623T>C 
CFTR c.4389G>A NEB c.581A>G 
CLN3 c.1158C>T NEB c.194C>T 
CLN3 c.1211A>G NEB c.25500T>G 
CLN3 c.242C>T NEB c.25309A>G 
CLN5 c.726C>A NEB c.25140C>T 
CLN5 c.528T>G NEB c.24538G>C 
CLN5 c.1103A>G NEB c.21690A>G 
CLRN1 c.57A>T NEB c.21341G>A 
COL4A3 c.3047G>A NEB c.20766C>T 
COL4A3 c.222G>A NEB c.20598C>G 
COL4A3 c.1668G>A NEB c.20192A>T 
COL4A3 c.2501A>G NEB c.18305G>C 
COL4A3 c.127G>C NEB c.18294T>C 
COL4A3 c.422T>C NEB c.16911A>G 
COL4A3 c.1195C>T NEB c.16762T>A 
COL4A3 c.1223G>A NEB c.16544A>C 
COL4A3 c.1352A>G NEB c.16542C>G 
COL4A3 c.1452G>A NEB c.10809G>C 
COL4A3 c.1721C>T NEB c.10707G>A 
COL4A3 c.3258G>A NEB c.9363T>C 
COL4A3 c.3807C>A NEB c.9124T>C 
COL4A3 c.4484A>G NEB c.8734T>C 
COL4A4 c.4207T>C NEB c.8466C>T 
COL4A4 c.3684G>A NEB c.8318G>A 
COL4A4 c.680G>A NEB c.7839G>C 
COL4A4 c.4932C>T NEB c.5971C>T 
COL4A4 c.4080G>A NEB c.4471G>A 
COL4A4 c.3011C>T NEB c.4435G>A 
COL4A4 c.2996G>A NEB c.4407G>C 
COL4A4 c.1634G>C NEB c.3901T>C 
COL4A4 c.1444C>T NEB c.3593A>G 
COL4A5 c.1992G>T NEB c.3081A>T 
CPS1 c.3643A>G NEB c.771T>C 
CPS1 c.3683G>A NEB c.571G>C 
CPS1 c.4252C>G NPC1 c.3797G>A 
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CPS1 c.-4_-3insTTC NPC1 c.2793C>T 
CPS1 c.1030A>G NPC1 c.2572A>G 
CPS1 c.1032C>T NPC1 c.2073G>A 
CPS1 c.2448C>T NPC1 c.1926G>C 
CPS1 c.2679C>G NPC1 c.387T>C 
CPS1 c.4217C>A NPC2 c.88G>A 
CPT1A c.2235G>A NPHS1 c.1596G>A 
CPT1A c.1296G>A NPHS1 c.658T>G 
CPT1A c.266G>A NPHS1 c.563A>T 
CPT1A c.1251T>C NPHS1 c.2970C>T 
CPT1A c.963G>A NPHS1 c.1110T>C 
CPT1A c.823G>A NPHS1 c.881C>T 
CPT2 c.1025T>C NPHS1 c.3315G>A 
CPT2 c.236A>C NPHS1 c.2971G>C 
CPT2 c.1806T>C NPHS1 c.2289C>T 
CPT2 c.1102G>A NPHS1 c.1320C>T 
CPT2 c.1939A>G NPHS1 c.1223G>A 
CTNS c.154G>A NPHS1 c.349G>A 
CTNS c.504G>A NPHS2 c.87C>G 
CTNS c.779C>T NPHS2 c.686G>A 
CTNS c.*300C>G NR0B1 c.498G>A 
CTSK c.831A>G NR0B1 c.114C>T 
CYP11B1 c.394C>T OPA3 c.231T>C 
CYP11B1 c.259G>C OTC c.137A>G 
CYP11B1 c.1086G>C OTC c.809A>G 
CYP11B1 c.873G>A PAH c.609C>T 
CYP11B1 c.246C>T PAH c.397A>C 
CYP11B1 c.225A>G PAH c.1242C>T 
CYP11B1 c.128G>A PAH c.529G>A 
CYP21A2 c.983C>T PAH c.1155C>G 
CYP21A2 c.318G>C PAH c.735G>A 
CYP21A2 c.308G>A PAH c.696G>A 
CYP27A1 c.674G>A PC c.3029C>T 
CYP27A1 c.888A>G PC c.1317C>T 
CYP27A1 c.1151C>T PC c.2619C>T 
DBT c.1150A>G PCCA c.762C>T 
DHCR7 c.1272C>T PCCA c.604G>A 
DHCR7 c.1158T>C PCCA c.1342A>G 
DHCR7 c.438T>C PCCA c.627A>G 
DHCR7 c.231C>T PCCA c.1423A>G 
DHCR7 c.207T>C PCCA c.1651G>T 
DHCR7 c.189G>A PCCB c.815G>A 
DLD c.543A>T PCCB c.911C>T 
DMD c.8762A>G PCDH15 c.5734G>C 
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DMD c.7183G>A PCDH15 c.4925G>C 
DMD c.6787C>T PCDH15 c.3709G>A 
DMD c.2391T>G PCDH15 c.1891G>T 
DMD c.2343C>A PCDH15 c.92-523T>C 
DMD c.1122G>C PCDH15 c.4596C>T 
DMD c.8810G>A PCDH15 c.5254_5256delCCT 
DMD c.7728T>C PCDH15 c.5104C>G 
DMD c.5234G>A PCDH15 c.4254A>G 
DMD c.3734C>T PCDH15 c.3817C>A 
DMD c.3021G>A PCDH15 c.2581G>A 
DMD c.2645A>G PCDH15 c.2291G>A 
DMD c.1635A>G PCDH15 c.960A>G 
DYSF c.1351A>G PCDH15 c.4982A>C 
DYSF c.2802G>A PCDH15 c.4853A>C 
DYSF c.3131G>A PCDH15 c.4487G>A 
DYSF c.356T>C PCDH15 c.4581C>A 
DYSF c.1120G>C PCDH15 c.2786G>A 
DYSF c.3191_3196dupCGGAGG PCDH15 c.1910A>G 
DYSF c.3641C>T PCDH15 c.1304A>C 
DYSF c.5373G>A PCDH15 c.1263T>C 
DYSF c.5757T>G PCDH15 c.1138G>A 
DYSF c.383G>A PCDH15 c.55T>G 
DYSF c.393C>T PEX1 c.1509A>G 
DYSF c.509C>A PEX1 c.627G>A 
DYSF c.942C>T PEX1 c.3103G>A 
DYSF c.1369G>A PEX1 c.1579A>G 
DYSF c.1827T>C PEX1 c.2442C>T 
DYSF c.1860C>T PEX1 c.2331C>A 
DYSF c.2583A>T PEX1 c.2088A>G 
DYSF c.3972C>T PEX10 c.880A>G 
DYSF c.4008C>A PEX10 c.291A>G 
DYSF c.4068C>T PEX10 c.279C>T 
DYSF c.4504C>T PEX2 c.748T>C 
DYSF c.5859A>C PEX2 c.18G>A 
ERCC6 c.352C>T PEX2 c.550T>C 
ERCC6 c.631G>A PEX6 c.2644G>A 
ERCC6 c.4238A>G PEX6 c.1387A>G 
ERCC6 c.3689G>C PEX6 c.2816C>A 
ERCC6 c.3637A>G PEX6 c.2814G>A 
ERCC6 c.3289A>G PEX6 c.2426C>T 
ERCC6 c.3010C>T PEX6 c.2364G>A 
ERCC6 c.2751C>T PKHD1 c.11878G>A 
ERCC6 c.1397+8395C>T PKHD1 c.11832C>A 
ERCC6 c.1397+8063G>A PKHD1 c.4438A>G 
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ERCC6 c.1397+7671C>T PKHD1 c.9415G>T 
ERCC6 c.1196G>A PKHD1 c.8848G>A 
ERCC6 c.528A>G PKHD1 c.12143A>G 
ERCC6 c.411G>A PKHD1 c.11714T>A 
ERCC6 c.135C>G PKHD1 c.11696A>G 
ERCC8 c.435T>C PKHD1 c.11525G>T 
ERCC8 c.363T>C PKHD1 c.10521C>T 
EVC c.276G>A PKHD1 c.9402G>A 
EVC c.1528G>A PKHD1 c.9237G>A 
EVC c.1971C>T PKHD1 c.7764A>G 
EVC c.2626G>A PKHD1 c.7587G>A 
EVC c.569G>T PKHD1 c.6950T>C 
EVC c.1304G>A PKHD1 c.5896C>T 
EVC c.1653G>A PKHD1 c.5608T>G 
EVC c.221A>C PKHD1 c.3756G>C 
EVC c.249A>G PKHD1 c.2489A>G 
EVC c.341C>T PKHD1 c.2278C>T 
EVC c.969T>C PKHD1 c.2046A>C 
EVC c.1026G>C PKHD1 c.1736C>T 
EVC c.1068A>G PKHD1 c.1587T>C 
EVC c.1115C>T PKHD1 c.1185T>C 
EVC c.1320T>A PKHD1 c.234C>T 
EVC c.1346C>A PKHD1 c.214C>T 
EVC c.1727G>A PMM2 c.590A>C 
EVC c.2279G>A PMM2 c.712C>T 
EVC c.2505G>A PMM2 c.324G>A 
EVC2 c.913G>T POMGNT1 c.1867A>G 
EVC2 c.904T>A POMGNT1 c.1666G>A 
EVC2 c.2405G>T POMGNT1 c.681A>G 
EVC2 c.2350A>G POMGNT1 c.178A>C 
EVC2 c.2017A>G POMGNT1 c.620A>G 
EVC2 c.1730T>C PPT1 c.309T>C 
EVC2 c.870G>A PPT1 c.401T>C 
EVC2 c.864C>T PROP1 c.59A>G 
EVC2 c.575C>G PROP1 c.27T>C 
EVC2 c.258G>A RTEL1 c.1403C>G 
EVC2 c.3253C>T RTEL1 c.1905C>T 
EVC2 c.2235A>G RTEL1 c.2019C>T 
EVC2 c.2095A>G RTEL1 c.2223T>C 
EVC2 c.2061T>C RTEL1 c.3254G>C 
EVC2 c.1437A>G RTEL1 c.3327C>T 
EVC2 c.688A>G RTEL1 c.2945C>T 
FAH c.267G>C RTEL1 c.3173C>A 
FAH c.1056C>T RTEL1 c.371A>G 
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FANCA c.2267G>C RTEL1 c.654T>C 
FANCA c.*385C>G RTEL1 c.1008G>A 
FANCA c.3807G>C RTEL1 c.2064T>C 
FANCA c.3654A>G RTEL1 c.2184C>T 
FANCA c.3263C>T RTEL1 c.2346G>A 
FANCA c.2901C>T RTEL1 c.2856C>T 
FANCA c.2574C>G RTEL1 c.2857G>A 
FANCA c.2426G>A RTEL1 c.3198A>C 
FANCA c.2151G>T SACS c.2580A>G 
FANCA c.1927C>G SACS c.9682A>G 
FANCA c.1235C>T SACS c.9666G>T 
FANCA c.1143G>T SACS c.9372T>A 
FANCA c.796A>G SACS c.2146C>T 
FANCC c.77C>T SACS c.1373C>T 
FANCC c.1200C>T SACS c.124A>G 
FANCC c.626G>A SACS c.12304T>C 
FANCC c.584A>T SACS c.11032C>G 
FKRP c.1411C>T SACS c.10338G>A 
FKRP c.135C>T SACS c.10291G>C 
FKTN c.166C>T SACS c.10106T>C 
FKTN c.608G>A SACS c.9981T>C 
FKTN c.1026C>A SACS c.8853T>C 
FKTN c.1336A>G SACS c.6195T>C 
FMR1 c.414G>A SACS c.4466A>G 
GAA c.286A>G SACS c.2080G>A 
GAA c.395G>C SACS c.1656A>G 
GAA c.348G>T SACS c.696T>A 
GAA c.1830C>T SGCA c.933C>T 
GAA c.2417C>T SGCB c.799C>T 
GAA c.324T>C SGCD c.756G>A 
GAA c.596A>G SGCD c.15G>C 
GAA c.642C>T SGCD c.775_777delAAG 
GAA c.668G>A SGCD c.84T>C 
GAA c.921A>T SGCD c.290G>A 
GAA c.1203G>A SGCG c.267A>G 
GAA c.1374C>T SGCG c.228T>C 
GAA c.1581G>A SGCG c.312T>G 
GAA c.2133A>G SGCG c.347G>A 
GALC c.550C>T SGCG c.705T>C 
GALC c.537T>C SGCG c.860A>G 
GALC c.41C>G SGSH c.1367G>A 
GALC c.1921A>G SGSH c.1159G>A 
GALC c.1698A>T SGSH c.1081G>A 
GALC c.1685T>C SLC12A6 c.260A>T 
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GALC c.1620A>G SLC12A6 c.1551G>C 
GALC c.1350C>T SLC12A6 c.1236G>A 
GALC c.984G>A SLC12A6 c.475C>T 
GALC c.742G>A SLC17A5 c.899C>T 
GALC c.330C>T SLC17A5 c.886G>A 
GALC c.75C>A SLC17A5 c.606A>G 
GALC c.61G>C SLC17A5 c.246G>A 
GALC c.42G>C SLC22A5 c.810C>T 
GALC c.49G>A SLC22A5 c.285T>C 
GALT c.652C>T SLC22A5 c.807A>G 
GALT c.940A>G SLC26A2 c.1474C>T 
GCDH c.861C>T SLC26A2 c.1721T>C 
GCDH c.1173G>T SLC26A2 c.2065A>T 
GJB2 c.457G>A SLC26A4 c.209C>T 
GLA c.235G>A SLC26A4 c.1195T>C 
GLB1 c.1306C>T SLC37A4 c.527+1delG 
GLB1 c.469G>T SLC37A4 c.467C>T 
GLB1 c.1594A>G SMPD1 c.89T>G 
GLB1 c.1561T>C SMPD1 c.1643C>G 
GLB1 c.34T>C SMPD1 c.138_143delGCTGGC 
GLB1 c.29C>T SMPD1 c.719G>A 
GLDC c.2858C>G SMPD1 c.729C>T 
GLDC c.1545G>A SMPD1 c.1460C>T 
GNE c.1863C>T SMPD1 c.636T>C 
GNPTAB c.3598G>A SMPD1 c.1071C>T 
GNPTAB c.1931C>T SMPD1 c.1522G>A 
GNPTAB c.1932A>G SMPD1 c.1749G>A 
GNPTAB c.18G>A STAR c.361C>T 
GRHPR c.14G>A STAR c.189A>G 
GRHPR c.343G>A TAT c.92C>T 
GRHPR c.579A>G TAT c.309G>A 
GRHPR c.963G>A TAT c.43C>T 
HADHA c.652G>C TCIRG1 c.1245G>C 
HADHA c.474C>T TGM1 c.270T>A 
HBA1 c.341T>A TGM1 c.1146C>A 
HBB c.180G>A TGM1 c.726G>A 
HBB c.9T>C TH c.1348G>A 
HEXA c.1306A>G TH c.303T>C 
HEXA c.9C>T TH c.174C>T 
HEXB c.185T>C TH c.813G>A 
HEXB c.362A>G TH c.360G>A 
HEXB c.619A>G TH c.334G>A 
HGSNAT c.1839C>T TMEM216 c.28C>T 
HGSNAT c.1749T>C TMEM216 c.432-11_432-10insA 
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HLCS c.1920C>T TMEM216 c.264G>A 
HLCS c.971G>A TMEM216 c.432-1G>C 
HLCS c.834C>T TPP1 c.1615G>T 
HLCS c.286G>A TPP1 c.1044C>T 
HLCS c.126G>T TPP1 c.293C>T 
HMGCL c.795C>G TTPA c.359-3delT 
HMGCL c.654A>G USH1C c.1414G>A 
HOGA1 c.363G>C USH1C c.403G>A 
HOGA1 c.474A>G USH1C c.1557G>C 
HOGA1 c.396G>A USH1C c.1440C>T 
HOGA1 c.912C>A USH1C c.1188A>G 
HSD17B4 c.420A>T USH2A c.13364C>T 
HSD17B4 c.1174G>A USH2A c.10666G>A 
HSD17B4 c.1876T>G USH2A c.8827G>A 
HSD17B4 c.317G>A USH2A c.7685T>C 
HSD17B4 c.1531T>C USH2A c.6713A>C 
HYLS1 c.468A>G USH2A c.3945T>C 
HYLS1 c.-80-3126C>G USH2A c.13297G>T 
HYLS1 c.-81+2379C>G USH2A c.11815G>A 
HYLS1 c.-80-3471G>A USH2A c.9650A>T 
HYLS1 c.-80-2955C>A USH2A c.9008T>C 
HYLS1 c.-80-2826A>C USH2A c.7718G>A 
HYLS1 c.91T>C USH2A c.6875G>A 
IDUA c.299+3564C>T USH2A c.2522C>A 
IDUA c.1174C>T USH2A c.14074G>A 
IDUA c.299+2336C>T USH2A c.14050T>C 
IDUA c.299+2351A>G USH2A c.12666A>G 
IDUA c.299+3221G>A USH2A c.12612A>G 
IDUA c.299+3476C>A USH2A c.11946G>A 
IDUA c.299+3632G>C USH2A c.11602A>G 
IDUA c.510G>A USH2A c.11504C>T 
IDUA c.299+1115G>A USH2A c.10232A>C 
IDUA c.299+1277G>C USH2A c.9595A>G 
IDUA c.299+1323T>C USH2A c.9430G>A 
IDUA c.299+2072C>T USH2A c.9343A>G 
IDUA c.543T>C USH2A c.9296A>G 
IDUA c.891C>T USH2A c.8656C>T 
IDUA c.942G>C USH2A c.8624G>A 
IDUA c.1081G>A USH2A c.7506G>A 
IDUA c.1100C>T USH2A c.6506T>C 
IDUA c.1164G>C USH2A c.6317T>C 
IKBKAP c.2543C>A USH2A c.5013C>A 
IKBKAP c.1911T>C USH2A c.4994T>C 
IKBKAP c.934G>A USH2A c.4457G>A 
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IKBKAP c.751A>G USH2A c.2109T>C 
IKBKAP c.189C>T USH2A c.1931A>T 
IKBKAP c.3876T>G USH2A c.1419C>T 
IKBKAP c.1073G>A USH2A c.504A>G 
IKBKAP c.948G>A USH2A c.373G>A 
IKBKAP c.3473C>T VPS13B c.2471C>T 
IKBKAP c.3214T>A VPS13B c.3203C>T 
IKBKAP c.3069G>C VPS13B c.4881C>T 
IKBKAP c.2855A>T VPS13B c.6907C>T 
IKBKAP c.2490A>G VPS13B c.7920G>A 
IKBKAP c.1965C>T VPS13B c.2473G>A 
IKBKAP c.1926G>A VPS13B c.4847G>A 
IKBKAP c.1574G>A VPS13B c.6025G>A 
IKBKAP c.819C>T VPS13B c.7227G>A 
IKBKAP c.441G>A VPS13B c.7239C>T 
IVD c.970T>C VPS13B c.8978A>G 
IVD c.732C>T VPS13B c.9567T>C 
KCNJ11 c.801C>G VPS13B c.10124C>T 
KCNJ11 c.762G>A VPS13B c.10140G>T 
KCNJ11 c.678C>T VPS13B c.10294G>A 
KCNJ11 c.1154C>G XPC c.102G>A 
KCNJ11 c.1143G>A XPC c.2815C>A 
KCNJ11 c.1009G>A XPC c.2061G>A 
KCNJ11 c.808C>G XPC c.1881T>A 
KCNJ11 c.570C>T XPC c.1496C>T 
KCNJ11 c.561G>A XPC c.1475G>A 
KCNJ11 c.67A>G ZFYVE26 c.7055C>T 
LAMA2 c.1798G>A ZFYVE26 c.6918A>T 
LAMA2 c.2462C>T ZFYVE26 c.5784T>C 
LAMA2 c.2670A>C ZFYVE26 c.3722G>A 
LAMA2 c.1562C>T ZFYVE26 c.2887G>C 
LAMA2 c.8586T>C ZFYVE26 c.677G>A 
LAMA2 c.156C>T ZFYVE26 c.3334G>T 
LAMA2 c.381C>A ZFYVE26 c.2826G>A 
LAMA2 c.1491T>C ZFYVE26 c.1184G>T 
LAMA2 c.1856G>A ZFYVE26 c.1153A>T 
LAMA2 c.2799A>G ZFYVE26 c.987C>T 
LAMA2 c.3412G>A ZFYVE26 c.5678G>T 
LAMA2 c.4750G>A ZFYVE26 c.5672A>G 
LAMA2 c.4956C>G ZFYVE26 c.5612G>A 
LAMA2 c.5466A>G ZFYVE26 c.4370G>A 
LAMA2 c.5502G>A ZFYVE26 c.3308C>T 
LAMA2 c.6237G>A ZFYVE26 c.3210C>G 
LAMA2 c.6246G>A ZFYVE26 c.3118T>A 
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LAMA2 c.7760C>T ZFYVE26 c.2692A>T 
LAMA2 c.7830G>C ZFYVE26 c.2559G>A 
LAMA2 c.7845G>A ZFYVE26 c.2112T>C 
LAMA2 c.7906A>G     
        
ABCC8 c.3525C>T IDUA c.1467C>T 
ABCC8 c.2545G>A IDUA c.299+1657C>T 
ABCC8 c.1686C>T IDUA c.24C>A 
ABCD1 c.1683C>T IDUA c.60G>A 
ABCD1 c.1699C>T IDUA c.99T>G 
ABCD1 c.1700A>G IDUA c.299+1888C>T 
ABCD1 c.1744G>A IKBKAP c.2446A>C 
ABCD1 c.1748T>A IKBKAP c.2294G>A 
ABCD1 c.1816T>C IKBKAP c.1758T>G 
ABCD1 c.1823G>A LAMB3 c.67C>T 
ABCD1 c.1548G>A LAMC2 c.599C>A 
ACADS c.511C>T LRFN4 c.9G>A 
ADA c.22G>A LRFN4 c.1225G>T 
AGL c.3884G>A LRFN4 c.1880C>T 
AGL c.83-33C>T LRFN4 c.1725C>T 
AGXT c.26C>A MEFV c.605G>A 
AIRE c.901G>A MEFV c.495C>A 
AIRE c.99T>C MESP2 c.531G>A 
ALMS1 c.72_74dupGGA MESP2 c.561delG 
ALMS1 c.66_74delGGAGGAGGA MESP2 c.558G>A 
ALMS1 c.69_74delGGAGGA MESP2 c.558_581del 
ALMS1 c.70_71insCGG MESP2 c.558_569delGGGGCAGGGGCA 
ALMS1 c.72_74delGGA MESP2 c.558_581del 
ALMS1 c.72_74dupGGA MESP2 c.561G>A 
ALPL c.330T>C MESP2 c.573G>A 
ATM c.5948A>G MESP2 c.585A>G 
ATP7A c.4048G>A MESP2 c.597A>G 
ATP7A c.-21-2239C>T MLC1 c.1053T>C 
BBS1 c.1413C>T MLC1 c.1052_1053ins(33) 
BBS10 c.1442A>G MLC1 c.1031A>G 
CBS c.1080C>T MLC1 c.996T>C 
CBS c.573G>A MLC1 c.978C>T 
CDKL5 c.3003C>T MMAB c.57C>A 
CDKL5 c.3084G>A MMAB c.56G>A 
CFTR c.1234_1238delGCAAA MPI c.10C>T 
CFTR c.1265C>T MUT c.711A>G 
CFTR c.1312A>G MYO7A c.3503+12_3503+33del 
CFTR c.1360_1362delTTG MYO7A c.5860C>A 
CFTR c.1360_1362delTTG NAGLU c.1788C>T 
61 	  
CFTR c.1365G>T NBN c.553G>C 
CFTR c.1584G>A NEB c.15821A>T 
CLN5 c.4C>T NEB c.17635-3dupT 
CLN5 c.72A>G NEB c.16021T>C 
CLN5 c.223T>C NEB c.14370G>A 
CLN5 c.234C>G NEB c.13353C>T 
CLN6 c.34G>A NEB c.11077C>T 
COL4A3 c.1099G>A NEB c.16450G>A 
COL4A3 c.485A>G NEB c.14734A>G 
COL4A3 c.976G>T NEB c.5370G>A 
COL4A3 c.3325C>T NPC1 c.644A>G 
COL4A4 c.4548A>G NPHS1 c.1926A>G 
COL4A4 c.4207T>C NPHS1 c.3230A>G 
COL4A4 c.3979G>A NPHS1 c.791C>G 
COL4A4 c.3684G>A NPHS1 c.492C>T 
COL4A4 c.3594G>A NPHS2 c.102A>G 
COL4A4 c.1833T>C PEX10 c.6C>G 
COL4A5 c.247C>T PEX6 c.330C>G 
CYP11B1 c.1157C>T PEX6 c.302C>G 
CYP21A2 c.29_31delTGC PEX6 c.399G>T 
CYP21A2 c.118C>T PKHD1 c.11340T>C 
CYP21A2 c.138C>A PKHD1 c.3785C>T 
CYP21A2 c.188A>T POMGNT1 c.1257G>A 
CYP21A2 c.747C>G PROP1 c.640A>C 
CYP21A2 c.803C>T PROP1 c.636T>C 
CYP21A2 c.806G>C PROP1 c.630A>C 
CYP21A2 c.844G>T PROP1 c.629_630insCCCCCCCCCCCC 
CYP21A2 c.1125C>T PROP1 c.624_625insCCCCCCCCCCCC 
CYP21A2 c.1174G>A PROP1 c.425C>T 
DMD c.8489G>A PROP1 c.424G>A 
DMD c.4072-295T>G RTEL1 c.1800C>T 
DMD c.7096A>C RTEL1 c.1833G>A 
DMD c.4275A>G RTEL1 c.2618G>A 
DYSF c.2105C>T RTEL1 c.3047C>T 
DYSF c.570T>C RTEL1 c.1050G>A 
ERCC8 c.1123-3delT RTEL1 c.2123G>A 
EVC c.769C>T RTEL1 c.2616T>C 
EVC c.772T>C RTEL1 c.*61A>G 
EVC c.1854C>T SGCB c.21_23delGGC 
EVC2 c.3507C>T SGSH c.957G>A 
EVC2 c.2077G>A SLC12A6 c.3003C>T 
EVC2 c.52C>T SLC26A4 c.1790T>C 
FANCA c.12G>A SLC37A4 c.984+247C>T 
FANCA c.1501G>A SLC37A4 c.857G>A 
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FANCA c.17T>A SLC37A4 c.528delT 
FANCA c.3982A>G SLC37A4 c.526delT 
FKRP c.341C>G SLC37A4 c.1224G>A 
GAA c.2065G>A SLC37A4 c.1062C>T 
GAA c.2338G>A SMPD1 c.107_118delTGCTGGCGCTGG 
GAA c.2553G>A SMPD1 c.564dupC 
GCDH c.*161G>A SMPD1 c.567dupA 
GCDH c.*165A>G SMPD1 c.575G>C 
GLB1 c.76-4426C>T SMPD1 c.573T>C 
GLDC c.578A>G TCIRG1 c.479G>A 
GLDC c.2113G>A TCIRG1 c.1985G>A 
GLDC c.498T>C TCIRG1 c.166C>T 
GLDC c.190G>T TCIRG1 c.384C>T 
GLDC c.52G>T TH c.687G>T 
GLDC c.501G>A TPP1 c.1542A>T 
GLDC c.249G>A USH1C c.1285-7531C>T 
GNPTG c.67G>C USH1C c.1285-7619C>T 
HEXA c.1518A>G USH2A c.9262G>A 
HSD17B4 c.2182A>G USH2A c.13191G>A 
HSD17B4 c.1675A>G VPS13B c.5980A>G 
HSD17B4 c.2199C>T VPS13B c.9407A>T 
IDS c.937C>T VPS13B c.1206+33T>G 
IDS c.438C>T VPS13B c.9424A>G 
IDUA c.314G>A ZFYVE26 c.879G>A 
IDUA c.352C>T ZFYVE26 c.3365C>T 
IDUA c.1230C>G ZFYVE26 c.1844C>T 
IDUA c.1360G>A     
*The variants above the black bar had a GQ score>/=90 in all of the 44 Armenian 
individuals. The variants below the black bar are variants in which there was a GQ 
score<90 in at least one of the 44 Armenian individuals. The majority of these variants 
were likely present in at least one of the 44 Armenian individuals; however, some of the 
variants below the black bar may have been incorrect calls and may in fact not be present 
in this cohort.  
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APPENDIX B: List of the 176 Conditions in the Foresight Expanded Carrier Screen 
CONDITION GENE CONDITION  GENE  
11-Beta-Hydroxylase-
Deficient 
Congenital Adrenal 
Hyperplasia  
CYP11B1 Hydrolethalus Syndrome HYLS1 
21-Hydroxylase-Deficient 
Congenital Adrenal 
Hyperplasia 
CYP21A2* 
Hypophosphatasia, 
Autosomal 
Recessive 
ALPL 
6-Pyruvoyl-Tetrahydropterin 
Synthase Deficiency PTS Inclusion Body Myopathy 2 GNE 
ABCC8-Related 
Hyperinsulinism ABCC8 Isovaleric Acidemia IVD 
Adenosine Deaminase 
Deficiency ADA Joubert Syndrome 2 TMEM216 
Adrenoleukodystrophy: 
X-Linked ABCD1 
KCNJ11-Related Familial 
Hyperinsulinism KCNJ11 
Alpha Thalassemia HBA1/HBA2* Krabbe Disease GALC 
Alpha-Mannosidosis  MAN2B1 LAMA2-Related Muscular Dystrophy LAMA2 
Alpha-Sarcoglycanopathy 
(including Limb-Girdle 
Muscular 
Dystrophy, Type 2D)  
SGCA Leigh Syndrome, FrenchCanadian Type LRPPRC 
Alport Syndrome, X-Linked  COL4A5 Lipoamide Dehydrogenase Deficiency DLD 
Alstrom Syndrome  ALMS1 Lipoid Congenital Adrenal Hyperplasia  STAR 
AMT-Related Glycine 
Encephalopathy AMT 
Lysosomal Acid Lipase 
Deficiency LIPA 
Andermann Syndrome  SLC12A6 Maple Syrup Urine Disease, Type Ia  BCKDHA 
Argininemia ARG1 Maple Syrup Urine Disease, Type IB BCKDHB 
Argininosuccinic Aciduria  ASL Maple Syrup Urine Disease, Type II DBT 
ARSACS SACS Medium Chain Acyl-CoA Dehydrogenase Deficiency  ACADM 
Aspartylglycosaminuria  AGA 
Megalencephalic 
Leukoencephalopathy with 
Subcortical Cysts 
MLC1 
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Ataxia with Vitamin E 
Deficiency  TTPA 
Metachromatic 
Leukodystrophy ARSA 
Ataxia-Telangiectasia ATM Methylmalonic Acidemia, cblA Type MMAA 
ATP7A-Related Disorders ATP7A Methylmalonic Acidemia, cblB Type  MMAB 
Autosomal Recessive 
Osteopetrosis, Type 1 TCIRG1 
Methylmalonic Aciduria and 
Homocystinuria, cblC Type MMACHC 
Bardet-Biedl Syndrome, 
BBS1-Related BBS1 MKS1-Related Disorders MKS1 
Bardet-Biedl Syndrome, 
BBS10-Related BBS10 Mucolipidosis III Gamma GNPTG 
Bardet-Biedl Syndrome, 
BBS12-Related BBS12 Mucolipidosis IV MCOLN1 
Bardet-Biedl Syndrome, 
BBS2-Related BBS2 
Mucopolysaccharidosis, Type 
I 
(including Hurler Syndrome) 
IDUA 
Beta-Sarcoglycanopathy 
(including Limb-Girdle 
Muscular 
Dystrophy, Type 2E)  
SGCB Mucopolysaccharidosis, Type II IDS 
Biotinidase Deficiency BTD Mucopolysaccharidosis, Type IIIA SGSH 
Bloom Syndrome BLM Mucopolysaccharidosis, Type IIIB NAGLU 
Calpainopathy CAPN3 Mucopolysaccharidosis, Type IIIC HGSNAT 
Canavan Disease  ASPA Muscle-Eye-Brain Disease POMGNT1 
Carbamoylphosphate 
Synthetase I Deficiency CPS1 
MUT-Related Methylmalonic 
Acidemia MUT 
Carnitine Palmitoyltransferase 
IA Deficiency CPT1A MYO7A-Related Disorders  MYO7A 
Carnitine Palmitoyltransferase 
II 
Deficiency 
CPT2 NEB-Related Nemaline Myopathy NEB 
Cartilage-Hair Hypoplasia RMRP Niemann-Pick Disease, Type C NPC1 
Cerebrotendinous 
Xanthomatosis  CYP27A1 
Niemann-Pick Disease, 
Type C2 NPC2 
Citrullinemia, Type 1  ASS1 
Niemann-Pick Disease, 
SMPD1- 
Associated 
SMPD1 
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CLN3-Related Neuronal 
Ceroid 
Lipofuscinosis 
CLN3 Nijmegen Breakage Syndrome NBN 
CLN5-Related Neuronal 
Ceroid 
Lipofuscinosis 
CLN5 Northern Epilepsy CLN8 
CLN6-Neuronal Ceroid 
Lipofuscinosis, Type 6 CLN6 
Ornithine Transcarbamylase 
Deficiency OTC 
Cohen Syndrome VPS13B PCCA-Related Propionic Acidemia PCCA 
COL4A3-Related Alport 
Syndrome COL4A3 
PCCB-Related Propionic 
Acidemia PCCB 
COL4A4-Related Alport 
Syndrome COL4A4 
PCDH15-Related Disorders 
(including Usher Syndrome, 
Type 1F) 
PCDH15 
Congenital Disorder of 
Glycosylation, Type Ia  PMM2 Pendred Syndrome SLC26A4 
Congenital Disorder of 
Glycosylation, Type Ib  MPI 
Peroxisome Biogenesis 
Disorder, Type 3 PEX12 
Congenital Disorder of 
Glycosylation, Type Ic ALG6 
Peroxisome Biogenesis 
Disorder, Type 4  PEX6 
Congenital Finnish Nephrosis NPHS1 Peroxisome Biogenesis Disorder, Type 5  PEX2 
Costeff Optic Atrophy 
Syndrome OPA3 
Peroxisome Biogenesis 
Disorder, Type 6 PEX10 
Cystic Fibrosis CFTR PEX1-Related Zellweger Syndrome Spectrum PEX1 
Cystinosis CTNS Phenylalanine Hydroxylase Deficiency PAH 
D-Bifunctional Protein 
Deficiency  HSD17B4 
PKHD1-Related Autosomal 
Recessive Polycystic Kidney 
Disease  
PKHD1 
Delta-Sarcoglycanopathy  SGCD Polyglandular Autoimmune Syndrome, Type 1 AIRE 
Dysferlinopathy  DYSF Pompe Disease GAA 
Dystrophinopathies (including 
Duchenne/Becker Muscular 
Dystrophy) 
DMD 
PPT1-Related Neuronal 
Ceroid 
Lipofuscinosis 
PPT1 
ERCC6-Related Disorders ERCC6 Primary Carnitine Deficiency  SLC22A5 
ERCC8-Related Disorders ERCC8 Primary Hyperoxaluria, Type 1 AGXT 
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EVC-Related Ellis-Van 
Creveld 
Syndrome 
EVC Primary Hyperoxaluria, Type 2 GRHPR 
EVC2-Related Ellis-Van 
Creveld 
Syndrome 
EVC2 Primary Hyperoxaluria, Type 3 HOGA1 
Fabry Disease GLA 
PROP1-Related Combined 
Pituitary Hormone 
Deficiency 
PROP1 
Familial Dysautonomia IKBKAP Pycnodysostosis CTSK 
Familial Mediterranean Fever MEFV Pyruvate Carboxylase Deficiency PC 
Fanconi Anemia 
Complementation, Group A  FANCA 
Rhizomelic 
Chondrodysplasia 
Punctata, Type 1 
PEX7 
Fanconi Anemia, Type C FANCC RTEL1-Related Disorders  RTEL1 
FKRP-Related Disorders FKRP Salla Disease  SLC17A5 
FKTN-Related Disorders 
(including Walker-Warburg 
Syndrome)  
FKTN Sandhoff Disease HEXB 
Fragile X Syndrome FMR1* Segawa Syndrome TH 
Galactokinase Deficiency GALK1 Short Chain Acyl-CoA Dehydrogenase Deficiency ACADS 
Galactosemia GALT Sjogren-Larsson Syndrome ALDH3A2 
Gamma-Sarcoglycanopathy SGCG Smith-Lemli-Opitz Syndrome DHCR7 
Gaucher Disease GBA* Spastic Paraplegia, Type 15 ZFYVE26 
GJB2-Related DFNB1 
Nonsyndromic Hearing Loss 
and Deafness (including two 
GJB6 deletions) 
GJB2 Spinal Muscular Atrophy SMN1* 
GLB1-Related Disorders GLB1 Spondylothoracic Dysostosis  MESP2 
GLDC-Related Glycine 
Encephalopathy GLDC 
Steroid-Resistant Nephrotic 
Syndrome NPHS2 
Glutaric Acidemia, Type 1 GCDH Sulfate Transporter-Related Osteochondrodysplasia  SLC26A2 
Glycogen Storage Disease, 
Type Ia  G6PC 
TGM1-Related Autosomal 
Recessive Congenital 
Ichthyosis  
TGM1 
Glycogen Storage Disease, 
Type Ib SLC37A4 
TPP1-Related Neuronal 
Ceroid 
Lipofuscinosis 
TPP1 
Glycogen Storage Disease, 
Type III  AGL Tyrosinemia, Type I FAH 
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GNPTAB-Related Disorders GNPTAB Tyrosinemia, Type II  TAT 
GRACILE Syndrome BCS1L USH1C-Related Disorders  USH1C 
HADHA-Related Disorders 
(including Long Chain 
3-Hydroxyacyl-CoA 
Dehydrogenase Deficiency) 
HADHA USH2A-Related Disorders USH2A 
Hb Beta Chain-Related 
Hemoglobinopathy (including 
Beta Thalassemia and Sickle 
Cell Disease) 
HBB Usher Syndrome, Type 3  CLRN1 
Hereditary Fructose 
Intolerance ALDOB 
Very Long Chain Acyl-CoA 
Dehydrogenase Deficiency ACADVL 
Herlitz Junctional 
Epidermolysis 
Bullosa, LAMA3-Related 
LAMA3 Wilson Disease ATP7B 
Herlitz Junctional 
Epidermolysis 
Bullosa, LAMB3-Related 
LAMB3 X-Linked Congenital Adrenal Hypoplasia NR0B1 
Herlitz Junctional 
Epidermolysis 
Bullosa, LAMC2-related  
LAMC2 X-Linked Juvenile Retinoschisis RS1 
Hexosaminidase A Deficiency 
(including Tay-Sachs Disease) HEXA 
X-Linked Myotubular 
Myopathy MTM1 
HMG-CoA Lyase Deficiency  HMGCL X-Linked Severe Combined Immunodeficiency IL2RG 
Holocarboxylase Synthetase 
Deficiency  HLCS 
Xeroderma Pigmentosum, 
Group A XPA 
Homocystinuria caused by 
Cystathionine Beta-Synthase 
Deficiency 
CBS Xeroderma Pigmentosum, Group C XPC 
* Indicates that the gene is typically analyzed using a custom assay by the commercial laboratory 
(differs from this study, where exome sequencing was performed, as highlighted above in 
METHODS) Text	  Green:	  Indicates	  that	  testing	  is	  recommended	  by	  ACOG	  Text	  Purple:	  Indicates	  that	  testing	  is	  recommended	  by	  ACMG	  Text	  Blue:	  Indicates	  that	  testing	  is	  recommended	  by	  ACOG	  and	  ACMG	  	  
 
 
 
 
